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Bifidobacteria represent Gram-positive gut commensals of mammals, birds and 
insects. Certain bifidobacterial species are associated with various health benefits if 
present in adequate amounts in the human gastro-intestinal tract (GIT). Bifidobacteria are 
highly prevalent and abundant in the infant gut, though they decrease in abundance with 
increasing age of their human host. Bifidobacteria must overcome many challenges in 
order to survive in the human gut, such as competition by other gut microbes, exposure to 
bile salts/acids and a fluctuating pH, and nutrient starvation. One key factor to 
bifidobacterial survival in the gut environment is the ability of members of the genus 
Bifidobacterium to metabolise complex carbohydrates indigestible to the human host. In 
the infant gut such carbohydrates are supplied in breast milk, whilst in the adult diet 
complex carbohydrates are often derived from plant-based oligosaccharides ingested from 
the diet. In particular, members of the Bifidobacterium longum subsp. longum taxon are 
associated with plant-derived poly- and oligo-saccharide utilisation. The research 
described in this thesis studied the metabolism of certain plant-derived oligosaccharides 
by different strains in the B. longum subsp. longum taxon. Bile salts possess major anti-
microbial activity and act by disrupting the integrity of the bacterial cell membrane. 
Concentrations of bile salts/acids are highest in the small intestine and starting from the 
duodenum a decreasing gradient exists along the GIT with lowest bile concentrations in 
the large intestine. Therefore, if bifidobacteria are ingested as an active ingredient of a 
functional food, they encounter and must be able to survive bile stress if they are to be 
effective as a probiotic. This thesis examined biofilm formation of Bifidobacterium breve 
UCC2003 in response to bile stress and assessed this ability in terms of survival and 
genetic requirements.  
Chapter II of this thesis focused on an in silico annotated hydroxycinnamic acid 
esterase encoded within a genetic locus present in B. longum subsp. longum NCIMB8809 
suspected to be involved in plant-derived poly/oligosaccharide utilisation. Both this locus 
and encoded esterase were found to be conserved amongst several strains of the B. longum 
subsp. longum taxon. Through a number of experiments the function of the esterase was 
proven and the enzyme was characterised. Therefore, it is likely this esterase cleaves off  
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hydroxycinnamic acids commonly present as substituents on arabinose moieties present 
in certain plant-derived poly/oligosaccharides.  
Chapter III investigates the enzymatic degradation of plant-derived 
poly/oligosaccharides by B. longum subsp. longum NCIMB 8809. This strain was found 
to grow on various plant-derived glycans including arabinoxylan, arabinogalactan and 
XOS. In this chapter, three glycosyl hydrolase (GH) 43 enzymes, from a presumed plant-
oligosaccharide cluster described in Chapter II, were found to possess exo-α-L-
arabinofuranosidase or α-endo-arabinanase activity. Furthermore, these enzymes were 
found to elicit activity against arabino-oligosaccharide (AOS) substrates. Therefore, a 
novel locus involved in AOS plant-oligosaccharide utilisation was identified in certain 
members of the B. longum subsp. longum taxon.  
Chapter IV describes the investigation of a LacI-type regulator, designated here as 
AauR, present in the aau locus of B. longum subsp. longum CCUG 30698 and predicted 
to regulate transcription of the aau locus encoding various GH43 enzymes. The consensus 
AauR recognition motif previously predicted for this regulator in another B. longum 
subsp. longum representative was indeed also shown to be present in strain CCUG 30698. 
This study showed that AauR binds to its predicted operator sequences located at specific 
positions within the aau locus. Therefore, AauR is presumed to transcriptionally regulate 
this locus, likely mediated through an as yet unidentified effector.  
Chapter V explores biofilm formation of B. breve UCC2003 in response to high 
concentrations of bile and bile salts. Through experimentation it was found that various 
factors are involved in biofilm formation including extracellular polysaccharide (EPS) 
production, LuxS and fatty acid biosynthesis. The formation of biofilm was found to be 
protective against high concentrations of bile. Extracellular DNA production, proteins and 
EPS were all found to impact on biofilm formation. Therefore, the formation of biofilms 
in bifidobacteria is presumed to constitute a multi-factorial process in response to high 
concentrations of bile.   
This thesis represents novel information on the metabolism of plant-derived 
oligosaccharides, specifically HCA removal, AOS metabolism and AOS transcriptional 
regulation in B. longum subsp. longum taxon. The mechanism of biofilm formation in B.  
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breve UCC2003 was also investigated and this is the first report on the molecular 
players important for biofilm formation in bifidobacteria.  
Future research is required to further elaborate on the enzymatic steps that are 
required for AOS and arabinan metabolism by various B. longum subsp. longum strains 
in order to explain strain-specific differences on the basis of encoded GH activities. Also, 
further detailed analysis of transcriptional regulation of the aau genetic locus is needed to 
identify the molecular effector of the AauR regulator, as well as the precise location of 
the relevant promoter sequences and the manner by which AauR controls transcription of 
its target genes. Finally, additional experimentation is required to further investigate the 
biological roles of bifidobacterial biofilm formation in the gut. It will in particular be 
important to learn how biofilm formation is triggered by certain bile components and to 
what extent biofilm formation is important for colonisation and survival under in vivo 
conditions. Ultimately, the generated knowledge on plant glycan metabolism and biofilm 
formation will contribute to our understanding of how a bacterium can take up residence 
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Most members of the genus Bifidobacterium are gut commensals which represent 
Gram-positive, non-motile, saccharolytic, non-sporulating, anaerobic bacteria. Many 
bifidobacterial strains are considered probiotic and therefore are thought to bestow 
health benefits upon the host if present in sufficient viable numbers in the 
gastrointestinal tract (GIT). Bifidobacteria are highly abundant among the gut 
microbiota of healthy, full term, breast-fed infants, yet the relative average abundance 
of bifidobacteria tends to decrease as the human host ages. Because of the inverse 
correlation between bifidobacterial abundance/prevalence and health, there is an 
increasing interest in maintaining or restoring bifidobacterial populations in the 
infant, adult and elderly gut. In order to colonize and persist in the GIT environment, 
bifidobacteria must be able to metabolise complex dietary or host-derived 
carbohydrates and be resistant to various environmental challenges of the gut, in 
particular bile stress. This is not only important for the autochthonous bifidobacterial 
species colonising the gut, but also for allochthonous bifidobacteria provided as 
probiotic supplements in functional foods. For example, Bifidobacterium longum 
subsp. longum is a taxon associated with the metabolism of plant-derived 
poly/oligosaccharides in the adult diet, being capable of metabolising hemicellulose 
and various pectin-associated glycans. Many of these plant glycans are believed to 
stimulate the metabolism and growth of specific bifidobacterial species and are for 
this reason classified as prebiotics. There is also a gradient of bile along the GIT and 
bifidobacteria have adopted various approaches to respond to bile stress, including 
biofilm formation. In this review, we will discuss the general features of the gut 
microbiota, and elaborate on how factors, such as age, diet and the physical GIT 
environment, may influence the gut microbiota composition. Furthermore, the 
mechanisms by which bifidobacteria colonize and persist in the GIT environment will 
be covered with an emphasis on carbohydrate metabolism, including mechanisms of 
poly-/oligosaccharide degradation and uptake, as well as its associated regulation, 






General features of the Gut Microbiota 
The human gastrointestinal tract (GIT) contains trillions of microorganisms which 
represent all three domains of life, while also including non-living biological entities such 
as viruses and bacteriophages (1). This hugely diverse collection of intestinal 
microorganisms is termed the gut microbiota (2). Higher eukaryotes such as mammals, 
birds and insects all contain a particular assembly of microorganisms in their GIT and the 
presence of this gut microbiota is essential for normal intestinal development and a 
properly functioning physiology of the host (3). The GIT is the most densely populated 
body site with an estimated bacterial biomass that is in excess of 1.5 kg, although this 
biomass has also been estimated to be as low as 0.2 kg (4, 5). Notably, the composition 
and density of the gut microbiota varies along the GIT (Fig. 1.1A). The oral cavity 
contains an abundance of microbial species of high diversity (~700 different prokaryotic 





 cfu/ml with a distinct microbial composition (7, 8). Compared to the 
large intestine the proximal small intestine has a rather low abundance of microbial 
species, estimated at <10
3 cfu/ml (9), due to high immune activity, fast transit time and 
bile secretion, although the microbial density gradually increases towards the distal ileum, 
where it reaches density levels that similar to those found in the large intestine (10). The 
largest biomass of the GIT residues in the lumen of the colon and caecum, where its 
contents are rich in glycans and where bile concentrations are much lower than in the 
small intestine. In this review, we will focus on the GIT community composition in the 
colon. Despite the large quantity of microorganisms present in the large intestine, the 
majority of the gut-associated bacteria taxonomically belong to just five phyla: 
Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes and Verricomicrobiota (11-13). 
This contrasts with the microbiota of other human body sites, such as the skin, which in 
comparison is typically more diverse (14). The gut microbiota of a given individual may 
be classified as belonging to one of three enterotypes: enterotype 1, which is dominated 
by the Bacteroides taxon; enterotype 2, dominated by the Prevotella taxon; or enterotype 
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3, dominated by the Firmicutes taxon (15). However, the concept of enterotypes has been 
controversial and rather than stratification of the gut microbiota into these discrete groups 
it has been suggested that it is more likely that the gut microbiota is better represented as 
gradients of these groups (16-18). Members of the gut microbiota can be autochthonous, 
i.e. indigenously resident, or allochthonous, in which case they are perceived as transient 
GIT inhabitants, including pathogens. The gut microbiota composition between 
individuals is highly variable, although the overall species/strain composition within an 
individual’s gut microbiota, once an adult microbiota has been established, does not 
appear to vary considerably over time (14, 19, 20).  
The gut microbiota interacts with and influences the host, and has been claimed to be 
responsible for or contribute to vitamin production (21), host immune development (22), 
pathogen exclusion (23), glycan metabolism (24, 25), neurotransmitter signalling (26) and 
short chain fatty acid (SCFA) production (27). Certain bacterial groups, such as 
bifidobacteria and lactobacilli, represent components of the gut microbiota that are 
believed to bestow beneficial effects upon the host and are for this reason termed 
‘probiotic’ (28). The International Scientific Association for Probiotics and Prebiotics 
(ISAPP) definition of a probiotic is any live microorganism that bestows a health benefit 
upon its host when ingested in adequate amounts (28). This does not include 
microorganisms associated with fermented food production, for instance Streptococcus 
thermophilus, which is employed for yogurt production, and which does not have any 
reported health benefits.  
For obvious reasons, it is believed that an increase in abundance of probiotic species 
in the gut will benefit host health. On the other hand, if a disturbance in the microbiota 
invokes a compositional change in the community to allow unfavourable species to 
dominate, it may change the overall community-mediated immune balance to cause 
inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) or Crohn’s disease 
(29, 30). For example, loss of butyrate-producing species such as Faecalibacterium 
prausnitzii and Roseburia hominis is reported in individuals with UC or Crohn’s disease 
(31, 32). Antibiotics can also disturb the microbiota and although it has been reported that 
the community generally recovers to almost the pre-treatment state, it may still be 
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permanently altered from the initial composition (33-36). It must also be noted that there 
is no defined ‘healthy microbiota’ and it has been thought that the term ‘dysbiosis’, i.e. a 
state representing an altered, unhealthy microbiota, has been assigned too readily by 
supposedly undesirable changes in taxonomic presence or absence of certain microbial 
groups, although such changes did not appear to alter the overall metabolic abilities 
encoded by the microbiota (37, 38). Indeed, it has been reported that the combined 
metabolic functionalities encoded by the gut microbiota are well conserved despite inter-
individual variation in microbiota composition (39, 40).  
One strategy to remedy a ‘disturbed’ microbiota and/or reduce symptoms of GIT 
disorders, like IBD or irritable bowel syndrome (IBS), is to ingest ‘probiotic’ bacteria, 
which, when incorporated in so-called functional foods, must be regularly supplemented 
in sufficient quantities (28, 41, 42). However, stable engraftment of probiotic strains 
appears to occur in cases where the probiotic species introduces a novel metabolic ability 
or represents a species not present in the resident microbiota (43). Therefore, there is an 
interest in modulating the gut microbiota activities in order to treat ‘dysbiosis’ and 
(associated) GIT disease states.  
Development of the gut microbiota as we age.  
It is generally thought that colonisation of the human gut commences at birth. 
However, several studies have reported that infants are already exposed to microbes in 
the womb by the placental microbiome (44-46). This topic remains contentious as it has 
been suggested that these results are a result of sample collection contamination or 
contamination from DNA extraction kits, the latter often referred to as the ‘kitome’ (47-
51). Recent research reported the presence of bacterial DNA in the amniotic fluid and 
detection of SCFAs in the meconium (52, 53), although another recent study reported no 
evidence of a placental microbiome (54).  
Full term, vaginally born infants possess a microbiota that resembles that of their 
mother’s vaginal microbiota and is associated with higher counts of bifidobacteria and 
Bacteroides than infants born by caesarean section (55, 56). Infants born by caesarean 
section on the other hand have been found to harbour a gut microbiota with species that 
are typically associated with the skin, such as staphylococcal species (55), while lacking 
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certain taxa, e.g. Bacteroides, and being more prone to colonisation by opportunistic 
pathogens (57). One study has shown that vaginally born infants have a higher abundance 
of lactobacilli that are presumed to originate from the mother’s vaginal microbiome (55), 
although another study did not report this and instead saw the transmission of Bacteroides 
from mother to infant (57). Transmission of bifidobacteria and/or bifidobacterial 
species/strains shared by mothers and infants has also been reported (58-60). However, 
the effects of delivery mode on gut microbiota composition appear to be short term with 
observed differences disappearing after 6 to 12 months (61). In general, the inter-
individual infant microbiota composition tends to fluctuate more when compared to that 
of adults (62). The   (62-64). In contrast, the adult gut microbiota, as discussed in the 
previous section, is more stable over time when compared to infants; bifidobacteria are 
present but tend to be lower in abundance (3 % - 6 %) and bifidobacterial abundance 
appears to decline with age (65, 66). 
The elderly gut microbiome (individuals older than 65 years) has been shown to be distinct 
from that of other (i.e. non-elderly) adults, and to contain a lower abundance of the phylum 
Actinobacteria, which include bifidobacteria (66-68). The elderly gut microbiota, similar 
to the adult gut microbiome, elicits a greater inter- than intra-individually diversity, but in 
contrast was shown to be generally more unstable and possessing an increased relative 
abundance of Bacteroidetes (67, 68). However, greater instability and cumulative changes 
were observed for elderly individuals who resided in long term care as compared to 
individuals who were still living in the community (68, 69). Elderly subjects may also 
possess a gut microbiota with an increased abundance of the pathogen Clostridium 
perfringens (70). Interestingly, the gut microbiome of centenarians differs greatly from 
that of (other) elderly, with the former possessing an increased abundance of 
Proteobacteria and differences in the Firmicutes clostridial subgroup clusters, an example 
being Eubacterium linosum, which has been proposed as a biomarker species for 
longevity (71). Therefore, the gut microbiota develops and changes as the human host 
ages and understanding how and why the microbiota changes as we age may allow 
intervention and modulation of the microbiota to prevent and resolve disease states.   
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Many factors influence the composition of the gut microbiota and as mentioned 
above microbiota changes occur as we age, while diet, the physical environment of the 
GIT, the immune system, xenobiotics, host genetics, disease state and various other 
aspects are known to cause compositional changes of the gut microbiota (72). In the 
following sections we will focus on how diet and the physical environment of the GIT 
affect microbiota composition.    
 
The effect of diet on gut microbiota composition. 
Diet is a major factor in determining microbiota composition. It has been shown 
that even short-term dietary interventions may rapidly alter the gut microbiota (73). 
Dietary fibres are carbohydrates, including lignin, with 10 or more monomeric subunits 
that cannot be hydrolysed by enzymes found in the small intestine of humans. Dietary 
fibres include i) naturally occurring carbohydrate polymers in consumed foods, ii) 
carbohydrates that are extracted physically, chemically or enzymatically from raw foods, 
such as fresh fruit and vegetables, and that have a physiological benefit, and iii) synthetic 
carbohydrates with a physiological benefit. Plant carbohydrate polymers under 10 
monomeric subunits, but between a degree of polymerisation (DP) of 3 and 9, can be 
classified as dietary fibres but this is decided at a national level and not by the Codex 
Alimentarius Commission (74). Glycan is a broader term that refers to complex 
carbohydrates (polymers and oligosaccharides), which are generally indigestible to the 
human host, yet can be metabolised by the gut microbiota, and may include carbohydrates 
with less than 10 monomeric units, which may result from dietary fibre degradation by 
the gut microbiota (75). Dietary fibres/glycans are found in the plant cell wall (Figure 
1.2) (75) and are common components in cereals (76, 77), fruit (78, 79), vegetables (80, 
81) and red grapes (82), thus being a typical constituent of the human diet; examples of 
these are fructo-oligosaccharides (FOS), inulin, pectin, arabinoxylan, xylan, arabinan, 
starch and lignin (83). This review will focus on plant-derived hemicellulose and pectic 
glycans, the structures of which will be described in more detail below. The microbial 
degradation of FOS, inulin and (indigestible) starch are not discussed in this review and 
the reader is therefore referred to a number of specific reviews on this subject (75, 84). 
Although many plant-derived glycans cannot be digested by the human host itself, 
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individual members of its gut microbiota encode a plethora of different, ‘Carbohydrate 
Active Enzymes’ (CAZyme) which facilitate the degradation of these complex, dietary 
fibre-derived saccharides (85). CAZymes are represented by (i) glycosyl hydrolases 
(GHs) which are responsible for the hydrolysis of glycosidic bonds, (ii) glycosyl 
transferases (GTs), that form glycosidic bonds, (iii) polysaccharide lysases (PLs), 
responsible for the non-hydrolytic cleavage of glycosidic bonds, (iv) carbohydrate 
esterases (CEs), that cleave ester bonds, and (v) auxiliary activities (AAs), which 
represent redox enzymes that act in concert with other CAZymes (86). There are currently 
168 GH families, 111GT families, 40 PL families and 18 CEs recognised in the CAZy 
database (http://www.cazy.org). The CAZyme profile of gut microbes is enriched for 
plant glycan-degrading enzymes, and despite community variation, this profile is 
conserved depending on the particular body site, indicating that the microbiome is adapted 
to carbohydrates present in the local GIT environment (87). 
 The microbiota composition of individuals from a ‘Western’ society in Europe 
and the USA, is distinct from that of rural communities in Africa and South America with 
a notable decrease in microbiota diversity in the former group (62, 88, 89). One of the 
main differences between these groups is the consumption of high amounts of plant fibre 
in rural communities; for instance, rural children from Burkino Faso aged between 1-2 
years and 2-6 years consumed 10 g/day (2.26 % of total diet/day) and 14.2 g/day (3.19 % 
of total diet/day) of fibre, respectively, whereas children from the EU aged between 1-2 
years and 2-6 years consumed 5.6 g/day (0.67 % of total diet/day) and 8.4 g/ (0.9 % of 
total diet/day), respectively (88). Other studies comparing the Hadza hunter-gatherers 
with ‘Western’ populations recorded that less than 10 % of the Western diet consists of 
plant fibre, whilst the Hadza diet is known to predominantly consist of plant-based, high-
fibre foods (89, 90). Consumption of fibre alters the gut microbiome in becoming enriched 
for enzymes involved in the degradation of plant-derived, complex poly/oligo-saccharides 
(62, 88, 91). Diets lacking in such fermentable carbohydrates may cause depletion or even 
extinction of corresponding fibre-metabolising microbial species in the gut (92). One way 
to modulate the gut microbiota is by dietary means through the supplementation of so-
called prebiotics, which are defined as ‘a substrate that is selectively utilised by host 
microorganisms conferring a health benefit’ (93). Among the first prebiotics that were 
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included in foods as functional ingredients were complex carbohydrates such as FOS and 
galacto-oligosaccharides (GOS) (94). Prebiotics that specifically stimulate bifidobacterial 
growth are termed ‘bifidogenic’ (94, 95). The definition of prebiotic, however, does not 
include fibres, such as pectin or xylan, which stimulate growth of a broad range of species 
in the GIT (93). It should also be noted that the ISAPP widened the definition of prebiotics 
to not only include certain non-digestible oligo/polysaccharides, but also to incorporate 
other beneficial molecules such as polyphenols (93). Therefore, while some plant fibres 
are not ‘prebiotic’ themselves they may still contain prebiotic components such as 
polyphenols. The related term synbiotic represents a combination of a probiotic organism 
and a corresponding prebiotic, being supplied together to elicit a synergistic effect through 
increased abundance of the probiotic and its associated beneficial effect(s) (96, 97). 
Short chain fatty acids (SCFAs) are carboxylic acids that possess aliphatic chains 
between one and six carbons in length (98); butyrate, acetate and propionate represent 
SCFAs that are predominantly produced through microbial fermentation of 
carbohydrates, including those constituting dietary fibres/glycans (75, 99, 100). SCFAs 
have been shown to elicit various health benefits: butyrate is the main source of energy 
for enterocytes in the colon (101), while propionate and acetate induce apoptosis in colon 
cancer cell lines (102, 103) and loss of butyrate-producing species has been reported in 
the microbiome of patients with GIT disorders such as IBD (31, 32). Furthermore, a 
mouse model has shown that the G protein-coupled protein receptor Gpr41 is activated by 
propionate, pentanoate, butyrate and acetate, and this interaction influences energy 
harvest from the diet and host adiposity (104, 105). Moreover, murine diets that had been 
formulated so as to allow high acetate or butyrate production by microbial fermentation 
were found to protect against diabetes by decreasing autoreactive T cells and increasing 
the number of regulatory T cells, respectively, while a diet that produced both high acetate 
and butyrate levels reduced IL-21, a diabetogenic cytokine (106). Acetate production by 
B. longum subsp. longum from fructose fermentation has been shown to cause anti-
inflammatory effects and/or to block epithelial apoptosis in a murine model, thereby 
preventing translocation of the Shiga toxin produced by Escherichia coli O157:H7 into 
the bloodstream, and in this way providing protection against this gut pathogen (23). In 
addition, lactate, an organic acid (but not a SCFA), is a major metabolite produced during 
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microbial metabolism of fibres that is important due to its metabolic conversion into 
butyrate by particular gut commensals (107). SCFAs are also metabolised by certain 
members of the microbiota and are important in metabolic cross-feeding between species 
(108, 109). For example, B. longum subsp. longum is known to metabolise arabinoxylo-
oligosaccharides (AXOS) producing acetate, which Eubacterium rectale can then 
metabolise to produce butyrate (109). Therefore, dietary modulation of the microbiota is 
an interesting route to promote the abundance and metabolic activity of particular 
probiotic species in the GIT in order to increase production of SCFAs/lactate producing 
microbial species in the GIT. The recently coined concept of ‘postbiotics’ is relevant in 
this context as it refers to any beneficial metabolic end product, such as SCFAs, or 
microbial component, for example lipids, teichoic acids, peptides or peptidoglycan 
fragments, released following lysis of a (probiotic) bacterium (110). For instance, the 
supernatant of a F. prausnitzii culture was shown to elicit anti-inflammatory activity by 
reducing NF-κB and IL-1β in Caco-2 cells and reduced the severity of 
trinitrobenzenesulphonic acid-induced colitis in mice (111). The cell free supernatants of 
cultures of Propionibacterium acidipropionici or Propionibacterium freundenreichii, 
which contain the SCFAs acetate and propionate, induced cell apoptosis in colorectal 
carcinoma cell lines (103).  
Dietary fibres may also be decorated with hydroxycinnamic acids (HCAs), such 
as ferulic acid or chlorogenic acid (112). HCAs are phenylpropanoids which are 
composed of a nine carbon skeleton, include an aromatic ring with several hydroxyl 
groups, and which require esterases to remove them from a carbohydrate backbone (113-
116). HCAs that are in free form are absorbed in the small intestine (117). It should also 
be noted that HCAs that are linked to plant-derived polysaccharides, are not readily 
absorbed and therefore reach the colon (118). HCAs can only be released and made 
bioavailable by gut microbiota members that produce esterases to cleave the ester bond 
between the HCA and polysaccharide (119). HCAs are viewed as beneficial due to their 
properties as anti-oxidants (116, 120). The gut microbiota has also been shown to bio-
transform HCAs by decarboxylation and reduction (121-124), for example ferulic acid 
may be decarboxylated to form caffeic acid and/or reduced to form dihydroferulic acid 
(122). HCAs can act as external electron acceptors for various heterofermentative 
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bacteria, such as Weissella cibaria, Lactobacillus brevis, Lactobacillus curvatus, and 
Lactobacillus rossiae (125). For these bacteria HCA supplementation to their growth 
medium was shown to increase acetate kinase activity, thereby causing enhanced acetate 
production, an increased NAD(+)/ NADH ratio, and higher intracellular ATP levels. 
HCAs are also bactericidal and HCA-mediated damage to the cell membrane of 
Lactobacillus plantarum has been observed by transmission electron microscopy (126) 
and of Dekkera yeast species (127).  HCAs also inhibit growth of certain gut pathogens, 
such as C. perfringens (128), presumably through induced membrane damage. The 
definition of ‘prebiotic’ may in principle allow for the inclusion of HCAs although it is 
still unclear whether the positive effects of HCAs also apply to the human GIT 
environment and therefore in depth, mechanistic studies are needed to corroborate the 
purported benefits of these compounds (93, 129).  
Diet also has a major impact on the infant microbiome. For instance, breast-fed 
infants generally have a significantly higher abundance of bifidobacteria and lactobacilli 
compared to their non-breast-fed counterparts (64, 130). Breast milk itself may contain 
viable bifidobacteria, while it is rich in so-called human milk oligosaccharides (HMOs) 
(131, 132), which are highly specific growth substrates for particular bifidobacteria (133, 
134). It was also found that the cessation of breast feeding and introduction to solid foods, 
referred to as weaning, is thought to induce changes to a more adult-like microbiome in 
infants (64, 130).  
 
The gut environment – a compartmentalised environment.   
Another factor that influences the microbial community composition is the gut 
environment itself. It has previously been shown that the physical environment to which 
microbes are exposed shapes the microbial community found there (14). It must also be 
noted that different anatomical sites in the gut harbour particular microbial species (13). 
For example, the actual number of microbial species present in the small intestine is lower 
compared to that in the large intestine. It has also been observed that the microbial 
community associated with the mucosal layers of the GIT is different from that of the gut 
lumen (135). This is due to various factors such as oxygen content, pH, presence of bile 
acids, the specific immune response at particular sites and metabolic resources available 
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(Fig. 1.1A). Due to space considerations, this review will focus on bile acid and 
carbohydrate metabolism in the GIT environment.  
To reach the gut and colonise, the GIT microbiota must first pass through the 
stomach. The stomach is highly acidic due to the secretion of gastric acid and it is this 
property that makes the stomach inhabitable for most microbial species (136, 137), an 
exception being Helicobacter pylori which is highly adapted to acidic conditions (138). 
Different bacterial species residing in the GIT can grow at various pH values and this is 
an important factor in GIT colonisation (139). Additionally, in order for a bacterial strain 
to be considered a probiotic it must be able to survive the pH fluctuations that occur when 
it transits from the acidic stomach through the alkaline (due to bile secretion) environment 
of the upper part of the small intestine until it reaches the more or less pH-neutral large 
intestine (140).  
The small intestine is more alkaline and aerobic when compared to the large 
intestine, and generally simple, mostly monomeric sugars are absorbed by the host here 
(13, 141). Microbes found in the small intestine generally metabolise simple sugars rather 
than larger and more complex, fibre-type glycans (142). Microbes that are present in the 
small intestine are therefore competing with the host for simple sugars, although secretion 
of anti-microbial peptides, IgA and bile help control bacterial growth in this gut location 
(143-145). Indeed, bacterial overgrowth in the small intestine may lead to host 
malnutrition (146). Bile fluid, which contains high bile salt levels, is produced by the liver 
and stored in the gall bladder before secretion into the small intestine (147). Prior to 
secretion primary bile acids, i.e. chenodeoxycholic acid and cholic acid, may become 
conjugated with either taurine or glycine (145, 148). These conjugated bile acids, also 
called bile salts, can then be further metabolised by certain bacterial components of the 
gut microbiota. For example, bile salt hydrolases are responsible for the deconjugation of 
the amino acids from bile acids (149, 150). Furthermore, these deconjugated bile acids 
may be converted into secondary bile acids by the GIT microbiota by 7 α-
dehydroxylation, dehydrogenation and epimerization (145, 150) (Fig. 1.1B). Bile acids 
are highly bactericidal due to their hydrophobic properties which promotes their insertion 
into the cell membrane of bacteria thereby causing cytoplasmic leakage (145). Therefore, 
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it is not surprising that bile acids have an impact on the GIT microbiota (151). Bile acids 
are generally reabsorbed in the small intestine, although they may escape re-adsorption 
and be present in the large intestine (147). Consequently, a bile salt gradient exists along 
the GIT ranging from approximately 40 mM to 0.5 mM with highest bile salt 
concentrations in the small intestine and lowest concentrations in the large intestine (151, 
152). It should be noted that bile and bile salts have been shown to induce biofilm 
formation in certain gut commensals, most likely as a protective strategy to resist the 
deleterious effects of these compounds (153, 154), and this aspect will be dealt with in 
further detail below.  
The large intestine contains the highest density and overall number of microbes, 
and represents the site where dietary fibre metabolism takes place (75). Fibre metabolism 
in the large intestine is important in dictating the microbial ecology of the large intestine 
by contributing to the relatively low luminal pH, that ranges from 5.5 to 7.5 (155), and by 
producing SCFA (see above). Nonetheless, a low carbohydrate and high protein diet may 
cause excessive protein fermentation in the large intestine, which may lead to the 
production of toxic and carcinogenic metabolites and increases the risk of pathogen 
proliferation and infection (156, 75). Therefore, dietary fibre metabolism is the sole or 
main carbon and energy source for specific microbes in the large intestine and is key to 
maintaining a healthy large intestine. 
 
Plant glycans 
Dietary fibres are derived from plant cell wall polysaccharides (157). The plant 
cell wall consists of a matrix comprising of cellulose fibrils, hemicellulose, pectin and 
lignin (Figure 1.2) (84). Hemicelluloses are polysaccharides with β-1,4-linked backbones 
of xylose, mannose or glucose, to form (arabino)xylan, mannan, and xyloglucan or β-
glucan, respectively (Figure 1.3) (84, 158). Lignin is predominantly composed of 
dimerised phenolic compounds such as HCAs (158, 159). Pectin is composed of various 
highly variable polysaccharides including homogalacturonan (HG), xylogalacturonan, 
apiogalacturonan, rhamnogalacturonan I (RGI) and rhamnogalacturonan II (RGII) (160). 
Pectic polysaccharides all contain an α-1,4-linked galacturonic acid backbone (Figure 
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1.4) (161). HG is the simplest pectic polysaccharide, consisting of unsubstituted α-1,4-
linked galacturonic acid moieties, whilst RGI is associated with an α-1,4-linked, D-
galacturonic acid and rhamnose-containing backbone which can be substituted by other 
polymers such as galactan, arabinogalactan and arabinan (162). RGI can also be decorated 
with phenolic compounds such as HCAs that cross-link through hydrogen bonding the 
oligosaccharide with other carbohydrate or lignin components (163). RGII is the most 
complex chain, with a HG backbone substituted with over 20 different glycosyl linkages 
and 5 different side chains (164). The various chemical bonds found in and enzymatic 
degradation of hemicelluloses and pectic polysaccharides are discussed in more detail 
below. Many of the complex, insoluble plant-derived dietary glycans that arrive in the 
large intestine are degraded by particular, so-called key stone species, Examples include 
Bacteroides cellulosilyticus, Bacteroides caccae and Dysgonomonas gadei species that 
have been identified as key stone species for the degradation of type II arabinogalactan 
due to their extracellular endo-β-1,3-galactanase activity (165). Following extracellular 
degradation of these carbohydrates, soluble oligosaccharides are released, which may then 
become available as metabolic substrates for other gut commensals, such as 
bifidobacteria. For example, B. breve UCC2003 can cross feed on certain GOS released 
from larch wood arabinogalactan by Ba. cellulosilyticus (166). Species/strains that can 
only degrade a narrow number of glycans or are dependent on other bacteria to provide 
such glycans are termed ‘specialists’ and may become extinct if these specific substrates 
do not become available in the gut (75, 92).  
Metabolism of a particular glycan is typically regulated at the transcriptional level, 
where genes involved in the metabolism of such a glycan will only be transcribed in its 
presence with certain carbohydrates being preferentially metabolized over others (167). 
Different species or even different strains of a given species have evolved the ability to 
metabolise specific glycans. For instance, Bacteroides ovatus is able metabolise 
hemicelluloses, whilst Ba. thetaiotaomicron cannot utilize such saccharidic substrates 
(168). Strains belonging to B. longum subsp. infantis are typically capable of metabolising 
HMOs, whilst members of the closely related subspecies B. longum subsp. longum are 
not, yet are adapted to degrade certain plant glycans (169, 170). This division of resource 
utilization may be to avoid competition for carbon and energy sources between 
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species/strains. Furthermore, it should be noted that in the GIT microbes can live in 
microbial communities and mucosal layers, and that the presence of certain glycans in the 
gut can promote biofilm or microfilament formation (171, 172). Therefore, glycans 
represent a crucial factor in colonisation, persistence and survival of the gut microbiota in 
the large intestine.  
 
1.3. Bifidobacterial survival in the gut environment 
 
Bifidobacteria – general features.  
Bifidobacteria are members of the Actinobacteria phylum harbouring genomes 
with a relatively high G + C content (considered approximately 50 % and higher) (173). 
They have been isolated from the GIT of many mammalian species, including humans, as 
well as of insects and birds (174). Bifidobacterial species are also present in the human 
oral cavity and abiotic environments such as sewage (173, 175). Bifidobacteria were first 
observed by Henri Tissier in the stools of healthy breast fed infants (176). Originally, 
bifidobacteria were taxonomically assigned to the lactic acid bacteria (LAB), being 
classified as Lactobacillus bifidus in Bergey’s Manual of Determinative Bacteriology for 
much of the first half of the 20th century (177). Bifidobacteria employ a unique metabolic 
pathway for carbohydrate fermentation which is termed the fructose-6-phosphoketolase 
(F6PK) pathway or the ‘Bifid Shunt’ (177), which together with their distinctively high 
G + C content, above 50 %, justified their taxonomic classification as a genus from other 
LAB as was subsequently confirmed by 16S ribosomal RNA gene-based typing (178, 
179). The first bifidobacterial genome sequence, i.e. that of B. longum subsp. longum 
NCC2705, was published in 2002 (180). Bifidobacterial genomes range from 1.7 Mb 
(Bifidobacterium indicum) to 3.16 MB (Bifidobacterium scardovi) (181, 182). 
Interestingly, genomes from bifidobacterial species isolated from the insect gut tend to be 
smaller than those from bifidobacteria isolated from the mammalian gut (183).  
As mentioned above, the relative abundance of bifidobacteria has been shown to 
decrease following weaning and from adolescence into adulthood, when they are reported 
to be present at a relative abundance of between 3 % and 6 % (65, 66). For instance, 
bifidobacteria account for approximately 4 % relative abundance reported for adult 
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populations in Northern Europe (184). However, the prevalence of bifidobacteria in adult 
populations varies. Other studies, examining adult microbiomes from multiple countries 
have reported an enriched abundance of bifidobacteria in Japanese and Mongolian adult 
populations as compared to other adult populations (185, 186). However, it should be 
noted that the methods and procedures by which fecal samples were processed varied in 
each of these studies, which may have influenced the reported abundance values (187).  
The bifidobacterial species that are present in the human gut may vary depending 
on host age. One study reported that the B. longum subsp. longum taxon is associated with 
both the adult and infant gut, whilst B. breve is more frequently associated with the infant 
gut (188). In contrast, another study reported that B. longum subsp. longum and B. breve 
were both associated with the adult and infant gut (189). Bifidobacterium dentium has 
been found to be in higher abundance in the elderly gut microbiota although its natural 
niche is believed to be the oral cavity (190). One reason to explain why particular species 
of bifidobacteria are more prevalent in the infant or adult gut may be that they are 
specialised to metabolise particular dietary carbohydrates. For example, B. breve and 
Bifidobacterium kashiwanohense are generally capable of metabolising HMOs as a 
consequence of breast-feeding (134, 191), whilst B. longum subsp. longum are generally 
specialised in the metabolism of plant fibres found in the adult diet (170, 180). The type 
of sample taken for microbiome analysis may therefore determine which bifidobacterial 
species are more likely to be detected. Some bifidobacterial species may be autochthons 
of the gut, for example B. longum subsp. longum, and are therefore capable of gut 
colonisation, whilst other species not isolated from the human gut, for example B. 
animalis subsp. lactis are allochthonous and are unlikely to be capable of (human) gut 
colonisation (43, 192, 193). Certain bifidobacterial strains or species, such as B. longum 
subsp. longum, are considered probiotic and are associated with various health benefits to 
the host, such as pathogen protection including production of acetate to protect against 
enteropathogenic infection (23), sequestration of iron at the detriment of gut pathogens 
(194), competing for epithelial binding sites with pathogens (194), immune modulation 
through exopolysaccharide production (EPS) (195), alleviation of IBS symptoms when 
supplied as a probiotic (196), and reducing the risk of contracting rotaviral diarrhoea 
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(197). On the other hand, just a single report has implicated bifidobacteria to cause 
bacteraemia in severely immunocompromised patients (198).  
 
1.4. Plant-oligosaccharide utilisation by Bifidobacteria.  
 
The bifid shunt – a unique carbohydrate metabolic pathway 
As mentioned above, bifidobacteria possess a unique pathway for carbohydrate 
assimilation which is termed the F6PK pathway (177, 199). This complex pathway, with 
its key enzyme fructose-6-phosphoketolase, is very distinct from the homofermentation 
(Embden-Meyerhof-Parnas) or heterofermentative (phosphoketolase or pentose 
phosphate) glycolytic pathways (200, 201) and is exclusively found in the 
Bifidobacteriaceae family and members of the Coriobacteriales order (202-204). The 
F6PK pathway can convert both hexose and pentose sugars by fermentation into SCFAs 
(205), with a theoretically yield of 1.5 mol acetate and 1 mol of lactate for every mol of 
glucose consumed (177, 206), or a 1:1 ratio of lactate and acetate in the case of pentose 
sugar fermentation (203). However, the actual ratio of acetate to lactate produced depends 
on various factors including the individual strain, pH and growth rate, which in turn differs 
depending on the carbohydrate substrate utilised (203, 207, 208). High rates of sugar 
metabolism have been shown to produce more lactate, whereas slower rates of sugar 
consumption produce proportionally more acetic acid, formic acid and ethanol (209, 210). 
Bifidobacteria also produce millimolar amounts of succinic acid which was found to 
regenerate NAD
+ (209). The F6PK pathway theoretically produces 2.5 molecules of ATP 
per 1 metabolised glucose molecule, which is higher than the energy yield of 
homofermentation by lactobacilli species which yields 2 molecules of ATP per 1 molecule 
of glucose metabolised (203).  
 
Carbohydrate import. 
Bifidobacteria are capable of metabolising a diverse range of mono-, di-, and 
oligo-saccharides found in the GIT environment, which they mainly import into their 
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cytoplasm by means of ABC type transporters or major facilitator superfamily (MFS) 
transporters, such as proton symporters and proton-motive force-driven permeases (180, 
211). Furthermore, most bifidobacterial species encode Phosphoenol pyruvate -
Phosphotransferase systems (PEP-PTSs) (212, 213). Nonetheless, the number of encoded 
ABC transporters far exceeds that of other genome-specified carbohydrate transportation 
systems. For example, B. longum subsp. longum NCC2705 is predicted to encode 13 ABC 
type transporters, 3 MFS transporters, 1 PTS system, 1 glycoside pentoside cation 
symporter family transporter (GPH) and 1 major intrinsic protein family (MIP) transporter 
(214). Similarly, Bifidobacterium longum subsp. infantis ATCC15697 is predicted to 
encode 13 ABC transporter systems, including four ATP permeases, an ATPase and seven 
solute binding proteins (SBP) that are encoded by a 43 kb cluster dedicated to HMO 
utilisation (215). Carbohydrate-specific ABC transporters hydrolyse ATP in order to 
import carbohydrates against a chemical gradient (216). An ABC transport system 
typically consists of two transmembrane-associated proteins, which act as permeases to 
translocate the substrate across the membrane and two ATP-binding proteins that provide 
the energy required for transport (217). The nature of the internalized substrate, which can 
be a carbohydrate, peptide or other organic or inorganic molecules, of an ABC transporter 
system is determined by the fifth protein of the system, the so-called substrate binding 
protein (SBP), which binds the saccharidic substrate and presents it to the ABC transporter 
(217). SBPs specifically bind to a single substrate (or very related substrates) and this can 
affect growth rate of a strain on a less related substrate; for instance, the SBP of an ABC 
transporter specified by B. animalis subsp. lactis B1-04 binds preferentially to β-1,6-
galactobiose over β-1,4-galactobiose, and this may in part contribute to faster growth of 
this strain on the former substrate (218). The heavy reliance on carbohydrate-specific 
ABC transporters by bifidobacteria for internalisation of their carbon and energy sources 
may reflect the need for members of this genus to be versatile in metabolising a diverse 
range of carbohydrates, including various oligosaccharides present in the gut (219, 220), 
rather than relying on PEP-PTSs, which are mainly restricted to monosaccharide 
utilisation (221). For example, an ABC transporter was found to confer the ability of B. 
animalis subsp. lactis B1-04 to metabolise the tri-saccharide raffinose (and related 
oligosaccharides) and this strain was able to outcompete Ba. ovatus when both strains are 
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co-cultured on raffinose (222). However, as a representative of its species B. bifidum 
PRL2010 is an exception and preferentially utilises PEP-PTS systems to import 
carbohydrates as this strain degrades complex carbohydrates extracellularly, thereby 
releasing mostly monosaccharides, explaining why PRL2010 encodes just two ABC 
transporters and four PEP-PTS systems (213).  
 
Enzymatic degradation of plant-oligosaccharides by bifidobacteria.  
A relatively high percentage, 13.7 %, of the Bifidobacterium genus pan-genome 
is dedicated to carbohydrate metabolism (174, 183), and a similar percentage, 13.23 % 
and 12.5 %, when representative genomes of B. breve and B. longum subsp. longum, 
respectively, are scrutinized (223, 224). However, when considering the Bifidobacterium 
core genome, just 5.5 % of these genus-wide conserved genes is dedicated to carbohydrate 
metabolic pathways suggesting that in order to survive in the GIT environment the 
acquisition of carbohydrate metabolic genes in the accessory genome is important (183).  
Bifidobacteria like other members the gut microbiota possess CAZymes dedicated to the 
breakdown of glycans in the GIT environment. Enzymes were originally categorised by 
the particular enzymatic reaction type they catalysed and were given enzyme commission 
(EC) numbers based on this (225). Enzymes can in addition be classified into CAZy 
families, where a CAZyme is assigned to be a member of a given family if it exhibits 
significant amino acid sequence similarity with the biochemically characterised founder 
member of that family, therefore taking into account protein fold and primary sequence 
similarity rather than just the type of enzymatic reaction (226). Therefore, an EC number 
can be distributed amongst several GH families and a single GH family may contain 
multiple EC numbers (225). Carbohydrate utilization profiles may aid in the subspecies 
classification of strains as B. longum subsp. infantis is specialised in HMO metabolism, 
whilst B. longum subsp. longum is dedicated to the metabolism of plant-derived glycans 
(224). Additionally, a strain-specific GH profile may help in categorising a strain into the 
correct species as GH families GH8, GH70, GH72, GH79 and GH94 were specifically 
found in subspecies longum, whilst GH34 and GH83 were only found in subspecies 
infantis; similarly unique EC numbers for subspecies infantis included EC 2.4.1.230 
(kojibiose phosphorylase, GH65) and EC 3.2.1.18 (sialidase, GH33), whilst several EC 
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numbers were unique to the longum subspecies and included EC 2.4.1.4 (amylosucrase, 
GH13), EC 3.2.1.41 (pullulanase, GH13, GH49 and GH57), EC 3.2.1.45 
(glucocerebrosidase, GH3, GH5, GH30 and GH116), EC 3.2.1.31 (-glucuronidase, GH1, 
GH2, GH30, GH79 and GH154), EC 3.2.1.99 (arabinanase, GH43, GH49 and GH93), 
and EC 3.2.1.156 (reducing end xylose-releasing exo-oligoxylanase, GH8). Therefore, the 
enzymatic profile of a strain may aid taxonomic assignment (227). It must be noted that 
while these GH families are predicted to be encoded by the genomes of bifidobacterial 
species/strains examined in the above study, not all are currently affiliated with 
bifidobacteria in the CAZY database as such enzymes must first be purified and tested 
before they will be affiliated with a species/strain in the CAZY database.  
 
Hydrolysis of a glycosidic linkage between two monosaccharides is mediated by 
two catalytic carboxylic residues in the corresponding GH, one being a proton donor 
represented by an acidic amino acid, while the other acting as a proton acceptor and 
represented by a basic amino acid (Fig. 1.5) (228). The process of hydrolysis can occur 
by two distinct routes, either (i) by means of a single displacement mechanism which 
takes place in a single step and which results in the inversion of the anomeric centre, or 
(ii) by a double displacement mechanism involving two catalytic steps resulting in the 
retention of the anomeric centre following hydrolysis (228, 229).  
Inverting enzymes, involved in the single displacement mechanism, employ two 
catalytic amino acid residues in the catalytic site, typically glutamic or aspartic acid, that 
act as an acid and a base respectively, being typically 10 Å apart (228). The hydrolysis of 
a glycosidic bond in the single displacement mechanism begins with the protonation of 
the glycosidic oxygen by the acidic residue, whilst the basic residue activates a water 
molecule which then attacks and thereby hydrolyses the glycolytic bond (230). Retaining 
enzymes, which catalyse the double displacement mechanism, also have two catalytic 
residues that act as an acid and a base yet are approximately 5.5 Å apart (228). In the first 
step of the double displacement mechanism one residue initially protonates the glycosidic 
oxygen leading to the hydrolysis of the glycolytic bond and the formation of an 
oxocarbenium ion-like transition state. A glycosyl-enzyme intermediate is then formed by 
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the basic residue attacking the anomeric centre of the sugar thus concluding the first step. 
In the second step of the reaction, termed deglycosylation, the basic residue deprotonates 
a water molecule which in turn attacks the glycosyl-enzyme intermediate and results in 
the hydrolysis of glycosyl-enzyme intermediate (230). Enzymes that utilise the double 
displacement mechanism may under specific reaction conditions also catalyse the 
elongation of oligomers with new linkages, a process referred to as transglycosylation 
(229). For retaining enzymes if the nucleophile is instead a sugar molecule rather than a 
water molecule, for example under conditions of very high substrate concentration, 
transglycosylation may occur (228, 230, 231). Additionally, CAZymes can either degrade 
oligo- or polysaccharides at the end of the molecule, most commonly from the non-
reducing end, or in between individual saccharidic moieties, activities that are referred to 
as exo or endo activity, respectively (232). The remainder of this review will focus on 
bifidobacterial GHs and CEs that are known to be involved in plant-oligosaccharide 
degradation. 
 
Xylan and xylo-oligosaccharides (XOS).  
 
Bifidobacteria are capable of growth on several plant-derived poly/oligo-
saccharides and their derived monomers (207, 208). Specifically, the B. longum subsp. 
longum taxon seems to be particularly well adapted to plant-based carbohydrate utilisation 
(224). Hemicelluloses include carbohydrates that generally possess a β-1,4-linked 
backbone, for example xylan, which is composed of β-1,4-linked D-xylose moieties (158). 
Furthermore, this xylan backbone can be decorated or substituted with L- or D-arabinose, 
xylose, galactose and galacturonic acid (233). Based on the nature of these substituents 
xylan is further categorised into arabinoxylan (AX), glucoronoxylans (GX) and 
glucoronoarabinoxylans (GAX) (234). AX from corn may also contain α-1,2-linked 
galactose to arabinose side chains (235, 236) (Figure 1.3).In order to obtain access to the 
xylan/XOS backbone bifidobacteria must first remove the arabinose, xylose, galactose, 
HCA and other substitutions attached to the xylan or XOS backbone.  
Multiple enzymes are needed to degrade the xylan backbone. Xylanases or endo-
1,4-β-xylanases (EC 3.2.1.8, GH5, GH8, GH10, GH11, GH30, GH51 and GH98) are 
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endo-acting enzymes that hydrolyse the internal β-1,4 bond between ᴅ-xylose residues 
within a xylan polymer to produce XOS (with a degree of polymerisation of between two 
and nine) (Figure 1.6A) (237). Currently, no bifidobacterial strain/species is known to be 
able to grow on the large insoluble xylan backbone. Therefore, it is likely that in the GIT 
species such as Ba. ovatus, Ba. xylanisolvens or Ba. intestinalis degrade the xylan 
backbone into soluble XOS, which then becomes available for other species to utilise 
(238-240). Species such as B. longum subsp. longum and Bifidobacterium adolescentis, 
are able to metabolise xylan-derived XOS (241, 242) and several enzymes have been 
implicated in the degradation of this oligomeric substrate by bifidobacteria. β-ᴅ-
xylosidases (EC 3.2.1.7, GH1, GH2, GH3, GH43, GH51, GH52, GH54, GH116 and 
GH120) are exo-enzymes which can hydrolyse XOS starting at the non-reducing xylose 
residue. For instance, a β-1,4 xylosidase (EC 3.2.1.37) (GH51) from B. breve K-110 was 
shown to elicit activity against p-Nitrophenyl (pNp) β-ᴅ-xylopyranoside, yet was shown 
to elicit very limited activity against xylan (243). Furthermore, B. adolescentis 
LMG10502 encodes two β-xylosidases: XylB (GH120) which hydrolyses XOS but not 
xylobiose, and XylC (GH43), which hydrolyses xylobiose (244) (Figure 1.6B). In 
addition, the GH8 RexA or reducing-end, xylose-releasing exo-oligoxylanase enzyme 
(EC 3.2.1.156)(245) from Bifidobacterium adolescentis LMG10502 was shown to elicit 
limited activity against xylan, no activity against xylobiose or pNp-β-ᴅ-xylopyranoside, 
though was shown to exhibit activity against XOS with a DP of 3 and above (Figure 1.6C) 
(246). 
Transcriptional and proteome analysis of B. animalis subsp. lactis BB-12 grown 
on XOS revealed expression of a number of xylanases, β-xylosidases and ABC 
transporters (246). Bifidobacterial species/strains that are able to utilise XOS, such as B. 
longum subsp. longum and B. adolescentis, may only be able to metabolize XOS up to a 
degree of polymerisation (DP) of six, i.e. xylohexose due to size limitations of the 
corresponding XOS transport system (247, 248). It must also be noted that generally 
bifidobacterial CAZymes are intracellular although extracellular hydrolysis of XOS by an 
apparently extracellular bifidobacterial β-1,4-xylosidase has been reported for B. 




AX, AXOS, arabinan, arabinogalactan and corn GAX.  
 
The xylose residues in xylan and XOS can be mono-substituted with L-arabinose 
at the C(O)2 or C(O)3 positions or di-substituted with L-arabinose at both C(O)2 and 
C(O)3 positions, while these arabinose substitutions can either be α-1,2-linked or α-1,3-
linked (158, 249). Only a limited number of bifidobacterial species/strains, e.g. B. longum 
subsp. longum, are able to metabolize such arabinoxylan (AX) and arabinoxylo-
oligosaccharide (AXOS) glycans (109, 224, 250). Depending on the particular 
bifidobacterial species/strain different components of AX or AXOS are utilised. One 
study has grouped bifidobacterial species/strains into five groups depending on if and 
what AX, AXOS or XOS components are being metabolised: cluster I, metabolism of 
monosaccharides arabinose and xylose, but no metabolism of XOS or arabinose 
substituents; cluster II, metabolism of mono- or di-substituted arabinose, yet no utilisation 
of the XOS backbone; cluster III, utilisation of the XOS backbone but no utilisation of 
arabinose substituents; cluster IV, utilisation of both arabinose substituents and XOS, up 
to xylotetraose of AXOS; cluster V, utilisation of AXOS including up to xylohexaose 
XOS chains (251). Therefore, the presence of AX, AXOS and XOS in the GIT supports 
growth of various bifidobacterial species/strains either directly or indirectly through 
possible cross-feeding activities (249). In this sense, Ba. ovatus has been shown to support 
growth of B. adolescentis when they interact on simple xylans, such as wheat AX and 
birch glucoronoxylan (Rogowski et al., 2015). However, Ba. ovatus cannot cross-feed 
with Bifidobacterium sp. when they use complex dietary xylans, such as corn AX. The 
reason is that Bifidobacterium lacks the catalytic apparatus needed to metabolize the 
oligosaccharides released by Ba. ovatus into the media. This is consistent with the fact 
that B. adolescentis is unable to metabolise corn AX, even if it is pretreated with the 
glycoside hydrolases located in the surface of Ba. ovatus (Rogowski et al., 2015). 
 
Pectin is composed of multiple complex glycans that can be utilised by the gut 
microbiota (252, 253). Probably because of its complexity there are currently no known 
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bifidobacterial species that are able to directly metabolize pectin (Figure 1.4). It is 
therefore presumed that other gut commensals such as Ba. thetaiotaomicron degrade these 
large polymers extracellularly and that certain bifidobacterial species can then scavenge 
the released mono- and oligosaccharides, as shown previously by co-cultivation of B. 
longum subsp. longum with Ba. thetaiotaomicron in the presence of arabinogalactan 
(254). B. longum subsp. longum strains have been shown to grow on the pectic 
components arabinan and arabinogalactan (255, 256). Arabinan consists of an α-1,5-
linked L-arabinose backbone that can be mono- or di-substituted with either α-1,2-linked 
and/or α-1,3-linked L-arabinose (161). Type I arabinogalactan is usually linked to other 
pectin-associated glycans, whereas type II arabinogalactan is O-linked to a protein 
backbone. Both arabinogalactan types are key components of the plant cell wall (257, 
258). Type I arabinogalactan is composed of a β-1,4-linked D-galactose backbone 
substituted by α-1,5-linked L-arabinose, while type II arabinogalactan is composed of a 
β-1,3-linked D-galactose backbone that can be substituted with α-1,3-linked arabinose 
and α-1,6-linked galactose side chains (161, 165, 258).  
α-L-arabinofuranosidases (EC 3.2.1.55, GH1, GH2, GH3, GH5, GH39, GH43, 
GH51, GH54 and GH62) are exo-acting enzymes that can cleave arabinose moieties from 
the polymeric backbone of xylan, XOS, galactan or arabino-oligosaccharides (AOS) (259, 
260). Arabinofuranosidases typically remove mono-substituted α-1,2-linked and/or α-1,3-
linked arabinose from their particular substrate backbone (261, 262), although certain 
arabinofuranosidases are specialised in removing arabinose from a di-substituted substrate 
(262). The ability to degrade AXOS has been shown to be species/strain dependent and 
some bifidobacterial species/ strains are only able to metabolise the arabinose 
substitutions on XOS (251). An α-arabinofuranosidase (GH51) produced by B. longum 
subsp. longum has been shown to release arabinose from AX (260), while AbfA (GH43) 
from B. adolescentis was shown to remove arabinose residues from the C(O)2 and C(O)3 
positions of mono substituted xylose, and AbfB (GH51) and AXHd3 (GH43) were 
demonstrated to release arabinose residues from the C(O)3 of disubstituted xylose 
residues (262, 263). L-arabinofuranosidases can also act as exo-enzymes on arabino-
oligosaccharides present in arabinan or arabinogalactan; an α-L-arabinofuranosidase 
(GH1) from B. adolescentis was shown to possess exo-activity on α-1,5-linked arabino-
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oligosaccharides (DP 2-5) (264). Similarly, the B. longum subsp. longum ArafC (GH43) 
was shown to be capable of removing α-1,2-linked and α-1,3-linked arabinose side chains 
of AX and arabinan, yet ArafD (GH43) was shown to exhibit hydrolytic activity towards 
α-1,5-linked arabinan (255). α-L-arabinofuranosidases can also release arabinose side 
chains from galactose residues in arabinogalacatan; BlArafA (GH43) an α 
arabinofuranosidase produced by B. longum subsp. longum can release α-1,3-linked 
arabinose from β-1,6-GOS (265). Endo-α-arabinases (EC 3.2.1.99) hydrolyse the α-1,5-
linkage within the arabinan backbone (266) and it is likely that arabinofuranosidases must 
remove the L-arabinose substituents before the backbone can be effectively cleaved. -L-
arabinofuranosidases (EC 3.2.1.185, EC 3.2.1.185, GH127, GH142 and GH146) remove 
β–linked arabinose substitutions from plant-oligosaccharides; β-linkages are less common 
and found on type II arabinogalactan linked to plant cell wall proteins (267). In B. longum 
subsp. longum, β-arabinofuranosidases HypBA1 (GH127) and HypBA2 (GH121) release 
arabinose from β-1,2-linked arabinosaccharides (DP 2-3) linked to hyproxyline (268, 
269). Several bifidobacterial α-L-arabinofuranosidases and β-L-arabinofuranosidases 
have been reported in literature and their salient features are summarised in Table 1.1.  
Various enzymes are required to degrade plant-derived galactan. Exo-acting β-
1,3-galactanases (EC 3.2.1.145) cleave the β-1,3-D-galactose backbone of 
arabinogalactan even in the presence of β-1,6-D galactose side chains through an by-pass 
mechanism (165, 270). Exo-acting β-1,4-galactanases (no designated EC number) cleave 
terminal β-1,4-linked galactose bonds (258). An exo-β-1,3 galactanase, (GH43 subfamily 
24) (Bl1,3Gal) isolated from B. longum subsp. longum was shown to hydrolyse β-1,3-
linked galacto-oligosaccharides (DP between 2 and 5), de-arabinosylated larchwood 
arabinogalactan (271). This Bl1,3Gal enzyme was unusual as it had a higher activity for 
β-1,3-galactan when the latter substrate was substituted with β-1,6-side chains, apparently 
recognizing these side chains as a specificy determinant in the active site. Similarly, BgaA 
(GH2) of B. breve UCC2003 was shown to cleave β-1,3-linked galactobiose/triose (166) 
(Fig. 1.7A). An exo-β-1,6-galactobiohydrolase (Bl1,6Gal, GH30) from the same species 
was shown to degrade β-1,6 linked galactose (DP between 2 and 4) and β-1,6-galactan 
but was not able to degrade arabinose substituted substrates (265) (Figure 1.7B). 
Furthermore, depending on the linkage type of the galactan backbone degradation may 
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involve endo-acting β-1,3-galactanases (EC 3.2.1.181, GH30) (258), β-1,4 galactanases 
(EC 3.2.1.89, GH53) (272) or β-1,6-galactanases (EC 3.2.1.164, GH30) (258).  
In B. longum subsp. longum, an extracellular endo-acting β-galactanase, GalA, 
was found to be capable of cleaving β-1,4 and β-1,3-galactan linkages (273) (Figure 
1.7C). The extracellular GalA (GH52) homolog in B. breve UCC2003, which is present 
in certain strains of this species, was found to elicit hydrolytic activity towards galactan 
releasing GOS (274). GalA (GH52) is found in a galactan utilisation cluster in both B. 
breve UCC2003 and B. longum subsp. longum strains; this galactan utilisation cluster that 
encodes GalA, an ABC type transporter, and GalG (GH42), a β-galactosidase; was shown 
to be upregulated when this B. breve UCC2003 is cultivated on galactan and GOS as its 
sole carbon sources (256, 274). β-galactosidases (EC 3.2.1.23, GH1, GH2, GH35, GH39, 
GH42, GH59, GH147 and GH165) hydrolyse linkages between a galactose moiety and 
another sugar moiety and several β-galactosidases have been identified in B. bifidum, B. 
longum subsp. longum, B. longum subsp. infantis and B. breve, being able to hydrolyse β-
1,3, β-1,4 or β-1,6 linkages in GOS and HMO substrates (134, 275-278) (Figure 1.7D).   
Finally, the backbone or side chains of these plant-derived oligomers may also be 
substituted with HCAs. Most hemicelluloses and pectic plant polymers also have HCAs 
attached by an ester bond to the (O) 5 position of the sugar moiety (158, 279). HCA-
specific esterases (EC 3.1.1.73, CE1 and CE6) catalyse the hydrolysis of an ester bond 
between a HCA, for example ferulic acid and p-coumaric acid, and a sugar moiety 
(arabinose, galactose or xylose) on AX and pectin plant-oligomers (280). Esterases have 
an alpha/beta hydrolase fold, a consensus motif (Gly-X-Ser-X-Gly) and a catalytic triad 
consisting of Ser-His-Asp residues (281). Bifidobacterial esterases active against HCAs 
have been described, including the CaeA esterase, whose encoding gene is located within 
the same genetic locus as the genes encoding GH enzymes that are predicted to be 





Regulation of carbohydrate metabolism  
 
Carbon catabolite repression (CCR) refers to a global regulatory mechanism by 
which bacteria can preferentially metabolise the ‘optimal’ carbon source that has the 
greatest energy yield, amongst a mixture of carbon sources, and involves inhibition of the 
metabolic pathways of the less preferred carbon sources (283). This is important in the 
GIT environment where potentially multiple carbohydrate sources are present and the 
optimal carbon source must be consumed to increase chances of survival in the gut. There 
are many mechanisms of CCR and this can vary from species to species. For instance, 
CCR may involve transcriptional activation, transcriptional down regulation and 
translational regulation (284). In the CCR paradigm, many bacteria, such as Escherichia 
coli the ‘optimal’ substrate glucose is metabolised preferentially (285), whereas for B. 
longum subsp. longum and Streptococcus thermophilus lactose is preferentially 
metabolised over glucose (286-288). The preference of other sugars over glucose for 
metabolism is also termed reverse CCR (284). CCR-resembling regulation has previously 
been described in bifidobacteria. In particular, in B. breve UCC2003 a FOS utilisation 
cluster inducible by growth on sucrose or Actilight, a commercial FOS prebiotic, was 
shown to be downregulated in the presence of glucose and/or fructose - sucrose mixes 
(289). CCR may be important from an ecological perspective, as it may avoid 
species/strain competition for limited carbon sources in the gut environment (290). 
However, CCR is not the only model to describe the regulation of carbohydrate 
metabolism in bacteria. Indeed, B. breve and Corynebacterium glutamicum, both 
members of the Actinobacteria phylum, have been shown to globally regulate their central 
metabolic flux and control co-metabolism of multiple sugars (291, 292).  
In order to control gene expression, bacteria commonly employ transcription 
factors (TFs), which typically bind to a specific DNA sequence, termed an operator, close 
to a promoter sequence where it can activate or repress transcription activity initiated from 
that promoter (293). TFs generally possess a helix-turn-helix (HTH) motif which allow 
them to recognize the operator and a companion domain that can bind to ligands or interact 
with other proteins thereby controlling the HTH domain and consequently its DNA 
binding ability (294, 295). TFs are categorised into different families based on sequence 
 
28 
similarity, examples being represented by the well characterised LysR, OmpR, 
LacI/GalR, and AraC/XylS families (296). LacI-type TFs for example have a HTH DNA 
binding domain at their N-terminus, a core domain to bind sugar ligands and a multi-
merisation domain for the formation of dimers and/or tetramers (297). LacI-type TFs 
generally act as repressors, though they can also increase transcription of their target 
promoters (293). With regards to carbohydrate metabolism, the LacI-type TF typically 
acts to only allow expression of a given set of genes if the corresponding carbohydrate is 
present in the growth medium. For instance in E. coli, the cytoplasmic presence of 
allolactose, which indicates the presence of lactose in the environment, prevents binding 
of the LacI repressor to the lac operator sequence, thereby allowing the RNA polymerase 
access to the lac promoter region, and activating transcription of the lactose (lac) operon 
(298, 299). Similarly, LacI-type TFs in bifidobacteria typically act as carbohydrate-
specific transcriptional repressors and are therefore important allowing only appropriate 
expression of carbohydrate metabolism genes in the presence of the corresponding 
saccharidic substrate in the GIT environment. 
LacI-type transcriptional regulators are the most prevalent and abundant family of 
bifidobacterial TFs; in one study they were shown to account for 63 % of all identified 
regulators encoded by ten bifidobacterial genomes (300). TFs have been shown, in silico 
and in vitro, at a local level to control genes and/or operons involved in carbohydrate 
metabolism for various carbohydrates including HMOs (301), galactan (256), melezitose 
(302), AOS (303), FOS (289), ribose (304) and cellodextrin (305). Nonetheless, other 
types of TFs have been reported to be involved in transcriptional control of genes involved 
in carbohydrate metabolism. Examples are represented by a GntR-type TF for sialic acid 
utilisation (306), a so-called repressor open reading frame kinase (or ROK) TF for 
raffinose and stachyose metabolism (302), and a NagC/XylR-type repressor involved in 
sulfated sugar metabolism regulation (307) (Figure 1.8).  
Central carbohydrate metabolism in bifidobacteria is represented by the ‘Bifid 
Shunt’, which is regulated by two LacI-type regulators, designated AraQ and MalR1 
(292), employing a mechanism that is reminiscent to that reported for C. glutamicum 
(291). This mechanism of global carbohydrate regulation may be of advantage to 
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bifidobacteria in the GIT environment allowing these gut commensals to quickly and 
effectively respond to the various different types and structurally diverse glycans that can 
be present in the GIT at any given time.   
 
1.5. Bifidobacterial survival in response to bile.   
 
In the GIT environment, bifidobacteria also encounter bile acids and bile salts and 
due to the bactericidal properties of these compounds bifidobacteria have developed 
various strategies to deal with this imposed bile stress. Bile salt/acids target the bacterial 
cell membrane and exposure of bifidobacteria to bile acids reduces internal pH, disrupts 
the transmembrane potential and results in leakage of cytoplasmic contents (308). Growth 
of bifidobacteria in the presence of bile has been reported to result in loss of certain 
glycolipids from the cell membrane and a decrease in surface hydrophobicity (309). 
Conversely, porcine bile has been shown to increase bifidobacterial cell surface 
hydrophobicity (154). Similarly, in B. animalis subsp. lactis IPLA 4549 and a bile-adapted 
derivative, exposure to bile was shown to cause a decrease in membrane fluidity, changes 
in membrane fatty acid composition and cell surface protein content, a decrease in 
phospholipid ratios, and distortion of the cell surface including formation of membrane 
vesicles (310). Changes in the expression of fatty acid synthesis, generally 
downregulation, in several different species/strains of bifidobacteria, some of which were 
bile adapted, have been reported in response to bile exposure (311-313). The presence of 
an extracellular polysaccharide (EPS) layer around a bacterial cell may exert protective 
effects against bile stress. In B. animalis subsp. lactis bile exposure has been shown to 
induce EPS production, while EPS was also shown to elicit a protective effect against a 
porcine bile challenge in B. breve and bile salt exposure in B. breve and B. longum subsp. 
longum and B. pseudocatenulatum (195, 314, 315). The cell surface proteome is also 
altered upon exposure to bile. Expression of DnaK, which can act as a plasminogen 
receptor, and an enolase, was found to be upregulated in response to bile exposure and 
was hypothesised to facilitate colonisation of B. animalis subsp. lactis (316). Genes 
encoding oligopeptide uptake were also shown to be transcriptionally upregulated in B. 
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breve and B. longum subsp. longum in response to bile and oligopeptide uptake in the 
presence of bile has been demonstrated for B. longum subsp. longum (313, 317). 
Many bifidobacterial species/strains, such as human isolates belonging to B. 
longum subsp. longum and B. breve, are known to encode a bile salt hydrolase (BSH) 
which can remove the taurine- or glycine amino group from internalized bile salts to 
release deconjugated bile salts (318-323). Bacteria lacking BSH activity are therefore 
believed to be more susceptible to the bactericidal effects of bile acids/salts (324). BSH 
activity produced by certain bifidobacteria has been reported to detoxify bile acids, 
provide nutrients through release of the amino groups, alter the cell membrane by 
incorporating bile salts, and overall contribute to the persistence of such microbes in the 
gut environment (325). However, the exact mechanism by which bile acid deconjugation 
activity aids in bifidobacterial survival has yet to be elucidated. Certain bifidobacterial 
species possess efflux pumps to extrude bile acids/salts from their cytoplasm/membrane. 
The ctr gene in B. longum subsp. longum NCIMB 702259 encodes a cholate efflux 
transporter in the sodium/bile acid family of transporters, B. longum subsp. longum 
NCC2705 and B. breve UCC2003 specify major facilitator superfamily (MFS) 
transporters that confer resistance against bile/bile salts, while B. breve UCC2003 
additionally produces ABC transporters that confer resistance to sodium cholate (313, 
326, 327).  
When bile salts cross the cell membrane, often derived from bile acids 
deconjugated by extracellular BSH activity, they cause the acidification of the cytoplasm 
and adaption to bile stress also increases resistance to acid stress indicative of cross over 
between bile and acid stress adaption (328). In order to counteract cytoplasmic 
acidification due to bile acid exposure, B. animalis has been shown to possess a bile-
inducible F1F0 ATPase, which extrudes protons at the expense of ATP (while it can also 
produce ATP by allowing protons to flow into the cytoplasm) (329). Carbohydrate 
metabolism is also affected when bifidobacteria are exposed to bile. Bile-adapted strains 
of bifidobacteria have been shown to preferentially utilise maltose or glucose in contrast 
to the wildtype strain (330). In another study bile-adapted strains were shown to express 
different glycosyl hydrolase activities against synthetic substrates: for instance, one bile-
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adapted B. longum strain was shown to exhibit increased arabinofuranosidase activity 
against pNp-arafuranosidase (328). Therefore, bile appears to influence carbohydrate 
metabolism and this may be due to increased metabolic/energy requirements when coping 
with bile stress. Central metabolism is also influenced by bile, and an increase of the 
activity of xylulose 5-P/fructose 6-P phosphoketolase, which is a key enzyme in the bifid 
shunt, has been reported in both B. longum subsp. longum and B. animalis subsp. lactis 
(311, 331). It should be noted that various studies have been carried out with different 
concentrations of bile and different types of crude bile (porcine or bovine) or bile salts, 
and this is likely to cause variable responses to bile stress reported in literature. It has also 
been reported that biofilm in bifidobacteria is induced by bile and bile salts (154). 
Therefore, bifidobacteria have adapted a robust and multifaceted response to bile stress 
involving cell surface modification, altered carbohydrate metabolism and biofilm 
formation in order to survive in the GIT environment. 
 
1.6. Biofilm formation by bifidobacteria.  
 
Biofilm formation describes a process that occurs when micro-organisms live 
together in microbial communities either attached to a surface or in flocs, called micro-
filaments and are enclosed by an extracellular matrix (332, 333). It has been shown that 
many gut commensals can form biofilms in the GIT environment (153, 334). Therefore, 
it is likely that biofilm formation is a key strategy to survive and persist in the GIT 
environment. Biofilm formation is a complex and multi-step process. The initial stage of 
biofilm formation called attachment involves micro-organisms attaching to a surface 
either through non-specific electrostatic interactions caused by the physical properties of 
the surface, or by specific release of extracellular DNA (eDNA) which promotes further 
electrostatic interactions between the micro-organisms and the surface, or by the 
expression of cell wall-associated proteins that bind to ligands coated on the surface (335-
337). The next biofilm formation phase is the accumulation stage which involves protein-
protein interactions between cell wall associated proteins and/or ligands and secretion of 
an extracellular matrix (EM) (335, 337). The EM can be composed of protein, 
carbohydrates, such as EPS, and/or eDNA (338). This is then followed by the maturation 
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stage, during which further development of the biofilm structure takes place through 
continued EM secretion. Finally, the dispersal stage involves cells in a biofilm detaching 
in order to return to planktonic growth. Dispersal can involve DNases to cleave DNA in 
the EM (339), proteins with surfactant properties such as phenol-soluble modulins (340) 
and enzymes that degrade the carbohydrate component of the EM, such as Dispersion B 
which degrades the β-1,4-glycosidic bonds in the N-acetyl glucosamine-containing EM 
(341). Biofilms are often formed in response to environmental stress, such as acid stress, 
antibiotics, bile stress or nutrient starvation, in order to increase microbial survival (342-
344). Biofilm formation is commonly regulated by a process called quorum sensing; a cell 
density-dependent signalling system (345). One of the best characterised systems for 
quorum sensing-controlled biofilm formation present in a wide range of bacteria is that 
involving auto-inducer-2 (AI-2) (345). The AI-2 molecule is produced by the 
intracellularly located LuxS, a S-ribosylhomocysteinase, and released in the growth 
medium, where its concentration is sensed by a two component signaling receptor, which 
at a particular threshold AI-2 concentration will trigger biofilm formation (as well as other 
adaptive responses) (346) (Figure 1.9).  
Bifidobacteria have been reported to form biofilm and microfilaments in vitro 
when induced by bile and bile salts (by exposure to 0.5 % taurocholic acid or 5 % porcine 
bile) and in the gut environment (154, 172). The AI-2 quorum sensing system may be 
involved in bifidobacterial biofilm formation. It has previously been reported that 
transcription of the luxS gene is upregulated upon exposure of B. breve UCC2003 to bile 
(313). AI-2 production has been reported for several bifidobacterial species/strains and 
overexpression of LuxS from B. longum susbp. longum NCC2705 has been shown to 
induce and increase biofilm formation (347-349). However, there does not seem to be a 
complete AI-2 system in bifidobacteria as they appear to lack the typical AI-2 sensors 
LuxP and/or LsrB (349, 350). Currently, besides these studies little is known about biofilm 
formation in bifidobacteria. Therefore, more work is needed to ascertain what the 
molecular mechanisms of biofilm are in bifidobacteria and whether biofilm is important 




1.7. Discussion  
 
The GIT environment is a dynamic, highly competitive and challenging ecological 
niche for bacteria to colonise. The physical environment of the gut itself is diverse and 
subjects microbes to low acid conditions in the stomach, high concentrations of bile in the 
small intestine and microbial competition from the densest microbial population in the 
human body which is located in the large intestine. To further complicate matters, the diet 
of the human host changes as we age moving from breast milk in infancy to complex 
glycan fibres in adult hood. Therefore, in order to survive the GIT environment 
bifidobacteria must overcome acid stress, bile stress, be able to metabolise complex 
carbohydrates and be able to respond appropriately both metabolically and 
physiologically to the ever-changing conditions of the GIT environment. Bifidobacteria 
represent a key genus among the gut microbiota and are present in the gut throughout life 
from infancy, adolescence, adulthood to old age. They are seen as a general indicator of 
health due to their purported probiotic properties. Therefore, understanding how human-
specific members of this genus colonize, persist and survive in the GIT environment is 
crucial if we wish to harness their health-promoting capabilities. It is clear that the highly 
flexible and energy efficient carbohydrate metabolism of bifidobacteria gives these 
microbes an advantage in the GIT and enables them to metabolise a range of different 
carbohydrates from HMOs in breast milk to complex plant glycans in the adult diet. 
Specialisation of different species of bifidobacteria on specific carbohydrates is believed 
to allow this genus to occupy many metabolic niches in the GIT whilst avoiding niche 
competition among the various members of the Bifidobacterium genus. Furthermore, its 
apparently unique regulatory control of carbohydrate metabolism allows this genus to be 
flexible and efficient in its carbohydrate metabolism whilst in the gut. Furthermore, 
bifidobacteria have a diverse set of mechanisms to deal with bile acid exposure, 
representing a major bactericidal challenge in the GIT by, among others, modulating 
carbohydrate metabolism, bile salt efflux and biofilm formation. Bifidobacteria therefore 
seem to have developed a multi-faceted arsenal of approaches to survive the various 
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Table legend: L arf : L arabinofuranose, Xyl: D-xylopyranoside, ME: methyl group, Gal; galactose, OMe; 
o linked methyl group, AG; arabinogalactan, AX; Arabinoxylan; AXOS: arabinoxylo-oligosaccahrides; B. 
ll; Bifidobacterium longum subsp. longum, B. al; Bifidobacterium animalis subsp. lactis, B.b; 




Figure 1.1. Summary of the gut physical environment and bile acid/salt bioconversion by the gut microbiota.  
Different compartments of the gastrointestinal tract harbour different physical conditions e.g. oxygen, pH, bile acids, small chain fatty acids (SCFAs), 
anti-microbial peptides (AMPs) and transit time (motility) all vary. A summary of the various physical conditions along the gastrointestinal tract 
adapted from Reinoso Webb et al. (357) (A). A summary of some of the bile acid/bile salt conversions by the gut microbiota (B). Primary bile acids 
such as cholic acid (CA) and chenodeoxycholic acid (CDC) are conjugated in the liver with a taurine or glycine amino acid, thus becoming bile salts 
Taurocholic acid (TCA), Glycocholic acid (GCA), taurochenodeoxycholic acid (TCDC) and Glycochenodeoxycholic acid (GCDC). Bile salts are 
then secreted into the small intestine. The gut microbiota can then act on these bile salts with a bile salt hydrolase enzyme to deconjugate bile salts 
back into primary unconjugated bile acids. Most bile acids/salts are re-absorbed in the small intestine however some bile acids and salts escape 
readsoprtion and are also present in the large intestine.  Further modifications of bile salts by the gut microbiota include 7-α-dehydroxylation which 
converts CA and CDA into deoxycholic acid (DCA) and lithocholic acid (LCA). Bile salts, TCA and GDA can also be converted into 





Figure 1.2. Plant cell wall composition and associated plant oligosaccharides.   
The primary cell wall is composed of cellulose microfibrils, hemicellulose and pectin. The secondary cell wall contains cellulose microfibrils, 
hemicellulose and lignin. 
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Figure 1.3. Structure of hemicelluloses found in the plant cell wall. 
Hemicelluloses consist of a β-1,4-linked D-xylose backbone (xylan) that is acetyl group substituted. Glucoronoxylans (GX) the xylose backbone is 
substituted with D - glucuronic acid. Arabinoxylans (AX) have α-1,2-linked and α-1,3-linked arabinofuranose substitutions. The backbone can be 
mono- or di-substituted. Finally, glucoronoarabinoxylans (GAX) possess the same backbone and arabinose substitutions as AX, yet with additional 
D - glucuronic acid moieties that are α-1,2-linked to the backbone, as well as D-xylose and L-galactose moieties that are β-1,2-linked and α-1,2-




Figure 1.4. Pectin polysaccharides associated with the plant cell wall. 




















Figure 1.5. Summary of inverting hydrolysis, retaining hydrolysis and transglycosylation. 
Summary of inverting single displacement mechanism (A). Summary of retaining double displacement mechanism (B). Summary of 







Figure 1.6. Enzymatic degradation of xylan and XOS.  
Degradation of the xylan backbone to XOS by xylanases (A). Degradation of XOS by β –D- xylosidases (B). Degradation of XOS by a ‘Reducing 







Figure 1.7. Enzymatic degradation of galactan.  
Degradation of the galacatan by exo- β 1,3 or β 1,4 galactanases (A). Degradation of galactan by exo - β 1,6 galactanases  (B). Degradation of the 
galacatan by endo β 1,3 or β 1,4 galactanases (C). Degradation of a galactose- sugar moiety bond by β –galactosidases (D). Enzyme names indicated 





 Figure 1.8. General schematic of transcriptional repression by a LacI-type repressor. 
In the absence of the sugar effector molecule the LacI-type repressor binds the operator sequence, and blocks access of the RNA polymerase to the 
promoter region or prevents transcriptional progression of the RNA polymerase, thereby inhibiting transcription (A). When a sugar substrate is 
metabolized and enters the cell this substrate or a metabolic derivative will act as an effector molecule by binding to the LacI-type repressor protein 
changing its conformation in a manner that prevents the LacI to bind to the operator sequence (typically by preventing dimerization of the LacI-type 






Figure 1.9. The stages of biofilm formation.  
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2.1. Abstract  
Bifidobacterium longum subsp. longum, a common member of the human gut microbiota 
with perceived positive health effects, is capable of metabolising certain complex, plant-
derived carbohydrates which are commonly found in the (adult) human diet. These plant 
glycans may be employed to favourably modulate the microbial communities in the 
intestine. Hydroxycinnamic acids (HCAs) are plant phenolic compounds, which are 
attached to glycans, and which are associated with anti-oxidant and other beneficial 
properties. However, very little information is available regarding metabolism of HCA-
containing glycans by bifidobacteria. In the current study, a gene encoding a HCA esterase 
was found to be conserved across the B. longum subsp. longum taxon and was present in 
a conserved locus associated with plant carbohydrate utilisation. The esterase was shown 
to be active against various HCA-containing substrates and was biochemically 
characterised in terms of substrate preference, and pH and temperature optima of the 
enzyme. This novel HCA esterase is presumed to be responsible for the release of HCAs 
from plant-based dietary sources, a process that may have benefits for the gut environment 














2.2. Introduction    
Bifidobacteria are Gram-positive gut commensals of various mammals, insects 
and birds, where their presence is associated with a number of beneficial effects (1). Such 
beneficial effects include pathogen inhibition (2, 3), immune modulation (4, 5), reduction 
in the symptoms of irritable bowel syndrome (6) and cholesterol reduction (7). In humans, 
bifidobacteria are particularly abundant and prevalent in the infant gut, though their 
relative abundance reduces upon weaning and upon ageing of their host (8). Members of 
the Bifidobacterium genus commonly metabolise a range of dietary and host-derived 
carbohydrates, with the precise substrate nature of this versatile carbohydrate metabolism 
being strain/species specific (9). The ability to metabolise diet- and host-derived 
carbohydrates is believed to enable efficient bifidobacterial gut colonisation and 
persistence. For example, infant-associated bifidobacterial species/strains can typically 
metabolise human milk oligosaccharides (HMO) present in breast milk, while 
species/strains found in adults tend to metabolise various dietary plant polysaccharides 
(10-13).  
Members of the Bifidobacterium longum subsp. longum taxon have the capacity 
to metabolise various plant cell wall polysaccharides, such as arabinoxylan, and pectic 
components, such as arabinan (14-21). Therefore, these polymeric glycans are considered 
suitable substrates to stimulate growth of B. longum subsp. longum in the adult gut. Plant 
phenolic compounds, such as ferulic acid and p–coumaric acid, also sometimes referred 
to as hydroxycinnamic acids (HCAs), may be present as substitutes to the L-arabinose 
moieties of such plant polymers by means of ester linkages (22, 23). Although various 
studies have described aspects of arabinoxylan and arabinan metabolism, little is known 
about HCA metabolism by bifidobacteria.       
HCAs are commonly found in various foods, being present in cereals, fruit, 
vegetables and coffee, among others (24, 25). HCAs have been associated with a variety 
of beneficial effects, including diabetes resistance in rats (26), intestinal pathogen 
inhibition (27), inhibition of platelet aggregation (28), anti-oxidant and anti-carcinogenic 
activities (29). Several studies have shown that certain fungi possess HCA esterases with 
broad substrate specificity, while more recently it has been demonstrated that bacterial 
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species, including lactobacilli and bifidobacteria, produce esterases that cleave artificial 
HCA-containing substrates and are (presumed to be) capable of removing HCAs from 
plant substrates (30-35). Therefore, gut commensals that produce HCA-active esterases 
are believed to play a role in releasing HCAs from plant carbohydrates. It may be that 
HCAs must be first removed from the plant carbohydrate to give access to other enzymes 
involved in plant carbohydrate degradation. The purpose of HCA release may also 
provide an energy advantage to bacteria as it has been shown HCAs can be used as 
external electron acceptors (36, 37). Furthermore, HCAs can inhibit growth of spoilage 
bacteria in high concentrations and HCA metabolism is thought to detoxify inhibitory 
HCAs (38).   
Esterases and lipases are two important groups within the hydrolase class of 
enzymes. Both esterases and lipases cleave ester bonds, possess an α/β hydrolase fold and 
generally exhibit a consensus sequence of (Gly-X–Ser–X–Gly) around the catalytic triad 
residues Ser–His–Asp (39, 40). Esterases, in contrast to lipases, generally follow 
Michaelis-Menten kinetics and hydrolyse substrates that are less than six carbons in length 
(39, 41). Esterases can also be categorised into four groups based on substrate preference 
(42).  
In the current study we identified a hydroxycinnamoyl acid esterase-encoding gene, 
designated caeA, in the genome of members of the B. longum subsp. longum taxon, 
positioned within a conserved locus predicted to be associated with arabinoxylan and 
arabinan metabolism. Heterologous expression, purification and subsequent 
characterization of the CaeA protein demonstrated that it indeed represents a genuine 
esterase, as opposed to a lipase, and can cleave several HCA-containing substrates. The 
biochemical properties of the CaeA esterase were investigated and the optimal enzyme 
pH and temperature ascertained. Therefore, this hydroxycinnaminic esterase is another B. 





2.3. Materials and Methods 
Bacterial strains, plasmids, growth conditions and chemicals. Bacterial strains and 
plasmids used in this study are summarised in Table 1. Bifidobacteria were routinely 
cultured on Reinforced Clostridium Agar (RCA) or in modified deMan, Rogosa, Sharpe 
medium (mMRS) supplemented with 1 % (w/v) lactose (Sigma-Aldrich, Steinheim, 
Germany) and 0.05 % (w/v) cysteine–HCL (Sigma-Aldrich) (43). All bifidobacteria were 
cultivated under anaerobic conditions in a modular atmosphere-controlled system 
(Davidson and Hardy, Belfast, United Kingdom). Lactococcus lactis strains were grown 
in M17 broth (Oxoid, Basingstoke, Hampshire, United Kingdom) supplemented with 0.5 
% (w/v) glucose at 30°C. Where required media was supplemented with 5 g 
ml−1 chloramphenicol. For RCA ethyl ferulate plate assays, RCA medium was 
supplemented with 0.1 % (v/v) ethyl ferulate dissolved in 96 % ethanol. Methyl ferulate, 
ethyl ferulate, methyl p–coumaric acid, methyl sinapinate, methyl caffeic acid (caffeate) 
and feruloyl glucose were all dissolved in 96 % ethanol (Carbon Chemicals, Ringaskiddy, 
Ireland) and sourced from Carbosynth, Berkshire, United Kingdom. Para-nitrophenol (p-
Np) acetate, p-Np butyrate, p-Np octanoate and p-Np dodecanoate were purchased from 
Sigma–Aldrich. All ions were purchased from Sigma-Aldrich.  
Nucleotide sequence analysis. Bacterial genomes were assessed using the Artemis 
genome browser (44) employing the annotated genome of B. longum subsp. longum 
NCIMB 8809 genome (20). Nucleotide analysis was completed using the programs 
SeqMan and SeqBuilder of DNASTAR software (DNASTAR, Madison, WI, USA). 
Annotation of protein function and HMM-HMM homology detection, both under standard 
settings, were determined using BlastP and HHPred, respectively (45-48). Protein 
alignments were generated using Clustal omega (49). 
DNA manipulations. All DNA manipulations were carried out as previously described 
(50). Chromosomal DNA was isolated from B. longum subsp. longum NCIMB 8809 using 
the GenElute Bacterial Genomic DNA Kit (Sigma–Aldrich). Primers for genomic 
amplifications were synthesised by Eurofins (Ebersburg, Germany). Genomic PCR 
reactions were performed with Q5 High-Fidelity 2X Master Mix (New England Biolabs, 
Herefordshire, United Kingdom) or Taq PCR master mix (Qiagen GmbH, Hilden, 
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Germany). PCR products were cleaned using the Roche High Pure PCR Kit (Roche 
Diagnostics, Basel, Switzerland). Plasmid DNA was isolated using the High Pure Plasmid 
Prep Kit (Roche Diagnostics) with an added initial step of incubating resuspended cells 
with 30 mg ml
-1
 lysozyme (Sigma-Aldrich) at 37°C for 30 min. Restriction enzymes 
(Roche Diagnostics) and T4 (Promega) were used as per manufacturer’s instructions. 
Colony PCR was performed using Extensor Hi-Fidelity PCR Master mix (Thermo Fisher 
Scientific, Waltham, United States). DNA electroporation procedures for B. breve and L. 
lactis were as previously described (51, 52). The integrity of all constructs was confirmed 
by DNA sequencing (performed by Eurofins, Ebersburg, Germany).  
Plasmid construction for heterologous expression of caeA in B. breve UCC2003. To 
construct the pNZ44caeA overexpression plasmid, the gene encoding the cinnamoyl 
esterase (B8809_1755), designated here as caeA, was amplified from the genomic DNA 
of B. longum subsp. longum NCIMB 8809 as a template using the polymerase Taq PCR 
master mix and primers CaeAF and CaeAR. Primer sequences used in this study are listed 
in Table 2. The generated PCR amplicon was restricted using NcoI and XbaI, and ligated 
to pNZ44 that had been similarly restricted with NcoI and XbaI. The resulting plasmid 
construct was electroporated into L. lactis NZ9000 and transformants were selected for 
by Cm
R
 resistance. Transformants containing the desired recombinant plasmid were 
confirmed by colony PCR using Extensor PCR Master Mix. Plasmid DNA was extracted 
from such transformants and clone integrity was confirmed by sequencing, resulting in 
plasmid pNZ44caeA, which was then electroporated into B. breve UCC2003 using 
chloramphenicol selection.   
Ethyl ferulate plate assay. The ethyl ferulate plate assay was carried out as described 
previously with modifications (53). Bacterial cultures were grown in mMRS 
supplemented with 1 % (w/v) lactose overnight and were spot plated (10 µl) on to RCA 
with 0.1 % (v/v) ethyl ferulate. Plates were then incubated anaerobically for 72 hours at 
37°C. A zone of clearing on the RCA ethyl ferulate plate around the colonies was taken 
as an indication of esterase activity.   
Expression and purification of CaeA in L. lactis NZ9000. To construct the pNZcaeA-
His plasmid to achieve overexpression and purification of His-tagged CaeA, primers 
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CaeAHisF, which contained a sequence to add an in-frame N-terminal His-10 tag to the 
encoded CaeA protein, and CaeAHisR were used to amplify caeA from the genomic DNA 
template of B. longum subsp. longum NCIMB 8809 using Taq PCR master mix. The 
generated amplicon was digested with EcoRV and XbaI, and ligated to pNZ8150 digested 
with ScaI and XbaI. The ligation mixture was introduced into L. lactis NZ9000 by 
electroporation with Cm
R
 selection and positive clones were confirmed by colony PCR 
using Extensor PCR Master Mix and recombinant plasmid integrity was confirmed by 
DNA sequencing. For overexpression, 400 ml of M17 broth supplemented with 0.5 % 
glucose was inoculated (2 % v/v) with L. lactis NZ9000-pNZcaeA-His and incubated at 
30°C until an OD600nm of 0.5 was reached. Protein production was induced with purified 
nisin (5 ng ml−1) for 2 hours. Cells were then harvested by centrifugation and the His-
tagged CaeA protein was purified using the PrepEase His-tag protein purification kit 
(USB, Germany). Protein eluate fractions were analysed by SDS-polyacrylamide gel 
electrophoresis on a 12.5 % polyacrylamide gel (54) with the Color Prestained Protein 
Standard, Broad Range (11-245 kDa) ladder (New England BioLabs, USA). 
Polyacrylamide gels were then fixed and stained using a Coomassie Brilliant Blue to 
indicate which fractions contained the purified protein. Protein aliquots were dialysed 
overnight in 50 mM NaH2PO4-K2HPO4 buffer pH 7 using dialysis tubing (Medicell 
Membranes Ltd., London, United Kingdom) to remove imidazole remaining from the 
protein purification. The amount of protein in each aliquot was determined by the 
Bradford Assay (Sigma–Aldrich) after dialysis (55).  
HPLC reactions. For High Performance Liquid Chromatography (HPLC) reactions, 
potential substrates methyl ferulate, ethyl ferulate, methyl p–coumaric acid, methyl 
sinapinate and  methyl caffeic acid were dissolved in 96 % ethanol to generate 20 mM 
stock solutions. Reactions were carried out in 20 mM morpholinepropanesulfonic acid 
(MOPS) pH 7.5 with the substrates present at a 1 mM final concentration and 15 µg of 
CaeA protein per reaction in a final reaction volume of 1 ml. Potential substrates were 
also incubated in buffer without CaeA as a negative control. All reactions and negative 
controls were incubated at 37°C for 16 hours and were terminated by the addition of 370 
µl ethyl acetate (Fisher Scientific) followed by centrifugation at 12,000 x g. The upper 
phase was then removed to a new tube and a further 370 µl of ethyl acetate was added, 
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followed by mixing and centrifugation at 12,000 x g. This second extraction was then 
used for analysis. The cinnamic acids and esters were detected, separated on an Agilent 
1200 series LC instrument coupled with an MSD Trap XCT Ultra Ion Trap mass 
spectrometer. Mobile phase A consisted of water + 0.1 % formic acid and mobile phase 
B consisted of Acetonitrile + 0.1 % formic acid. A highly refined and optimised gradient 
method was developed to separate all of the cinnamic acids and esters, and this was 
achieved in a 47 min run. The chromatography column used for separation was an Agilent 
Eclipse XDB C-18 column (150 mm x 4.6 mm), and the column oven was maintained at 
40°C. An injection volume of 5 μL was used for all injections with ethanol used as a 
needle wash and UV detection was completed in parallel to mass spectrometry as a 
detection system. UV wavelengths of 280 nm and 320 nm were selected for measurement 
purposes. 
For mass spectrometry-based detection, positive alternating mode was used, acquiring 
data in both positive and negative mode, though in general the detected analytes were 
more suited to negative mode analysis. A scan range of 100 – 2200 m/z was used with a 
capillary voltage of -3500 V, Nebuliser pressure of 50 psi, Dry gas (Nitrogen) was utilized 
at 10 L/minute, a drying temperature of 350°C was used and an m/z value of 220 was 
employed as the set target mass. The skimmer was set to 40 V, while the capillary exit 
was at 107.5 V. 
Substrate specificity assay. Enzyme reactions were carried out at 37°C in 0.1 M 
NaH2PO4- K2HPO4 buffer containing 0.6 % (v/v) Triton–X100 and 1.1 mg/ml of gum 
arabic (Sigma – Aldrich) at pH 7.5. 20 mM stock solutions of p-Np acetate, p-Np butyrate, 
p-Np octanoate and p-Np dodecanoate were prepared in 1:4 (v/v) acetonitrile: 
isopropanol. All reactions had a final substrate concentration of 6 or 12 µg/ml CaeA 
protein in a final reaction volume of 1 ml. Esterase enzymatic activity was measured by 
the release of p-Np from the substrates at the pH-independent wavelength 348nm. 
Reactions were terminated after 30 s by the addition of 25 µl of concentrated HCl (36 %) 
(Sigma–Aldrich). The rate of enzyme activity was calculated as µmol min
-1 mg-1 of p-Np 
released. The maximal enzyme activity observed was then defined as 100 % and the 
relative activity for each reaction was calculated accordingly. 
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Hydrolysis of ethyl ferulate, methyl ferulate, methyl p-coumaric, methyl sinapinate or 
methyl caffeate was determined using p-Np as a proton sink as previously described with 
modifications (56). A 10 mM stock solution of each substrate dissolved in 96 % ethanol 
was prepared. A 10 mM stock solution of p-Np (Sigma-Aldrich) was used to prepare 1 
mM NaH2PO4/ K2HPO4 buffer (pH 7) with p-Np at a final concentration of 0.44 mM. 
Assays were carried out in this buffer with 6 or 12 µg/ml CaeA and substrates at a final 
concentration of 1 mM in 200 µl at 37°C for 2 hr. The rate of the enzyme activity was 
calculated as µmol min
-1 mg-1 of HCA released with standard curves for each 
corresponding HCA.  
Optimal Temperature, pH and ions assay. A 20 mM stock solution of p-Np butyrate 
substrate was prepared in 1:4 (v/v) acetonitrile: isopropanol and 0.3 % (v/v) Triton–X100 
(All from Sigma-Aldrich). Enzymatic assays were performed at 20°C, 25°C, 30°C, 37°C, 
40°C, 50°C, 55°C for 30 s in 0.1 M NaH2PO4- K2HPO4 buffer at pH 7.5 with 6 µg/ml 
CaeA protein and a final concentration p-Np butyrate of 2 mM (100 µl) in a total reaction 
volume of 1 ml.  
For optimum pH assays, a stock of 20 mM p-Np butyrate was prepared in 1:4 (v/v) 
acetonitrile: isopropanol. Impact of pH on enzyme activity was determined at 37°C in 0.2 
M citric acid phosphate buffer (pH 3 – 5), 0.1 M NaH2PO4/ K2HPO4 buffer (pH 5 – 8) 
and 50 mM Tris HCL (7 – 9). All buffers also contained 0.6 % (v/v) Triton–X100 and 1.1 
mg/ml gum arabic. The pH-variable assays were performed for 30 s with 6 or 12 µg/ml 
of protein with a final concentration of p-Np butyrate of 2 mM in a total reaction volume 
of 1ml. For both assays, rate of enzyme activity was calculated as µmol min
-1 mg-1 of p-
Np released. The maximal enzyme activity was then defined as 100 % and relative activity 
for each reaction was calculated. Enzymatic activity was measured at the pH independent 
wavelength 348nms. 
The effect of metal ions on enzyme activity was also tested. Enzyme reactions were 
carried out at 37°C in 0.1 M NaH2PO4/ K2HPO4 buffer pH 7.5 in a microtiter plate. A 
stock of 20 mM of each ion was prepared in water. A stock of 20 mM p-Np butyrate was 
prepared in 1:4 (v/v) acetonitrile:isopropanol. Assays were performed in a final volume 
of 200 µl for 10 min with a final concentration of 6 µg/ml of protein and 2mM p–Np 
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butyrate. Ions were at a final concentration of 1 mM. Enzymatic activity was measured in 
all assays by the release of p-Np at the pH-independent wavelength of 348nm after 10 
min. The rate of the enzyme activity was calculated as µmol min
-1 mg-1 of p-Np released. 
The maximal enzyme activity was then defined as 100 % and relative activity for each 
reaction was then calculated.  
HPAEC-PAD analysis. The feruloyl glucose substrate was dissolved in ethanol. 
Reactions were carried out in 0.1 M sodium phosphate pH 7.5 with the substrate at a 0.5 
mg/ml final concentration and 15 µg of CaeA in a final reaction volume of 1 ml. A 
negative control including just feruloyl glucose and buffer (i.e. without enzyme) was also 
performed. Reactions and negative controls were incubated at 37°C for 16 hours and 
terminated by heating the sample at 98°C for 2 min. Standard solutions of 1 mg/ml glucose 
prepared in water and 0.5 mg/ml feruloyl glucose in ethanol were used. Standards and 
reactions were freshly prepared immediately prior to analysis. Samples were stored at 4°C 
before their assessment by High-Performance Anion Exchange Chromatography – Pulsed 
Amperometric Detection (HPAEC-PAD) analysis, which was performed employing a 
Dionex ICS-3000 system (Sunnyvale, CA) as follows. A 25 µl aliquot of each of the 
esterase reactions was separated on a CarboPac PA1 analytical exchange column (250 
mm x 4 mm) with a CarboPAC PA1 guard column (50 mm x 4 mm) and a pulsed 
electrochemical detector (ED40) in the PAD mode. All columns and detectors were 
acquired from Dionex. Elution was carried out at a constant flow-rate of 1.0 ml min−1 at 
30°C using the following eluents: eluent A, 200 mM NaOH; eluent B, 100 mM NaOH 
with 550 mM Na acetate and eluent C, MilliQ water. Analysis was performed using a 
linear gradient of sodium acetate with 100 mM NaOH from 0 min to 50 min, 0 mM; from 







Identification of an esterase-encoding gene conserved among members of the B. 
longum subsp. longum taxon. B. longum subsp. longum has the capacity to metabolise 
plant carbohydrates; for example, arabinofuranosidases have been annotated and/or 
studied from strains in this taxon (12, 57, 58). However, no esterases, enzymes involved 
with the removal of HCAs from plant phenolics, have curently been studied from this 
taxon. An in silico search for an esterase gene in the available genome sequences of 
members of the B. longum subsp. longum taxon using Blastn revealed a highly conserved 
locus (B8809_1751 – B8809_1762 in B. longum subsp. longum NCIMB8809), predicted 
to be involved in plant-derived oligosaccharide degradation within the B. longum subsp. 
longum taxon (12, 21, 59) (Figure 2.1). The locus includes genes predicted to encode (i) 
five arabinofuranosidases (B8809_1754, B8809_1757 – BB8809_1760), enzymes that are 
known to release arabinose moieties from certain plant polysaccharides such as 
arabinoxylan and arabinan; (ii) four ABC transporter permeases and a solute binding 
protein, which are presumed to be involved in the transport of arabinose into the cell 
(BB8809_1751 – 1753, BB8809_1761-1762); (iii) an esterase (BB8809_1755), and (iv) 
a LacI-type regulatory protein (B8809_1756), which may be responsible for 
transcriptional control of the genes of this locus. The gene product of B8809_1754, or 
AbfII2 as previously designated, exhibits 51% similarity to a previously characterised 
arabinofuranosidase from Streptomyces avermitilis NBRC14893 (60). The annotated 
esterase (corresponding to locus tag BB8809_1755) from B. longum subsp. longum 
NCIMB 8809 was selected for analysis and designated caeA (for cinnamoyl acid esterase 
A, its function as will be outlined below). HHPred-based analysis predicts that the CaeA 
protein shares a conserved structure with esterases from several bacterial species, while 
BlastP searches indicated that CaeA contains a conserved alpha-beta hydrolase domain 
which is typical of esterases (61). 
Sequence alignment of CaeA with several experimentally validated esterases, 
including an esterase from Bifidobacterium animalis subsp. lactis with activity against 
chlorogenic acid (30), showed the presence of the conserved Gly–X–Ser–X–Gly esterase 
hydrolytic motif around the Ser-His-Asp catalytic triad. The active site Ser is at the center 
of the Gly-X-Ser-X-Gly motif (Supplementary figure S2.1). However, these esterases 
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exhibit low sequence similarity to CaeA, ranging from 27 to 33 %. CaeA is predicted to 
represent a cytoplasmic protein as based on SignalP prediction (62). Since the caeA gene 
is located within a genetic locus presumed to be involved in arabinoxylan and arabinan 
metabolism, we speculate that CaeA may be involved in the removal HCAs from the 
arabinose residues in arabinoxylan, arabinan and perhaps other plant carbohydrates. For 
this reason we wanted to confirm the suspected esterase activity of CaeA against model 
HCA substrates.  
 
Heterologous expression and hydrolytic activity of CaeA. In order to assess if CaeA is 
able to hydrolyse ethyl ferulate, a model substrate for esterase activity (53, 63), caeA was 
cloned into the expression vector pNZ44 (64), to generate pNZ44caeA, and introduced 
into Bifidobacterium breve UCC2003 which does not contain a caeA homolog. B. breve 
UCC2003 WT, B. breve UCC2003 pNZ44 (negative control) and B. breve UCC2003 
pNZ44caeA were then spot plated on to RCA supplemented with 0.1 % (vol/vol) ethyl 
ferulate and a zone of clearance was observed arround the spotted colonies, indicating the 
breakdown of ethyl ferulate in the case of B. breve UCC2003 pNZ44caeA, indicating 
expression of esterase activity supplied by the CaeA protein, yet not for B. breve 
UCC2003 WT or B. breve UCC2003 pNZ44 (Figure 2.2). This result therefore supports 
the notion that CaeA is a functional esterase capable of hydrolysing ethyl ferulate. 
 
Protein purification of CaeA and enzymatic activity against model HCA substrates. 
In order to assess the enzymatic activity and substrate specificity of CaeA, a His-tagged 
version of this protein was expressed in L. lactis NZ9000 and purified by Ni–affinity 
chromatography. This His-tagged CaeA protein was shown to exhibit an approximate size 
of 36 kDa when analysed by SDS-PAGE (Figure 2.3), in agreement with the molecular 
mass (35.57 kDa) of the protein including the N-terminal His10-tag as determined by the 
ExPASY molecular weight calculator (65). An additional band, presumed to be a co-
eluted protein, is observed in the gel just above the CaeA protein band. For this reason we 
used a negative control in all enzyme assays described below, represented by a nisin-
induced L. lactis NZ9000 culture carrying the empty expression vector. The purified His-
tagged CaeA protein was tested for esterase activity against several substrates (i.e. methyl 
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ferulate, ethyl ferulate, methyl caffeate, methyl p–coumaric acid and methyl sinapinate) 
to determine substrate specificity, and to assign CaeA to either of the esterase sub-groups 
A, B, C or D. CaeA was shown to release the associated HCA from methyl ferulate, ethyl 
ferulate, methyl p–coumaric and methyl caffeate, while no noticeable activity was found 
against methyl sinapinate (Table 2.3 & Supplementary Figure S2.2). These results 
indicate that CaeA can be classified as a type B feruloyl esterase (42). A subsequent assay 
was employed to quantify the amount of HCA released once the ester bond of the HCA 
esters is hydrolysed. The obtained results demonstrate that CaeA can release HCA from 
methyl ferulate, ethyl ferulate and methyl caffeate, while there was no detectable activity 
against methyl sinapinate. Methyl p-coumaric and chlororgenic acid were also tested, 
however; due to the intrinsic properties of these substrates HCA release could not be 
accuratley measured in this assay.   CaeA was most active towards methyl ferulate under 
these conditions (Figure 2.4). This contrasts with the activity of the esterase from 
Lactobacillus plantarum WCFS1, which was shown to exhibit more activity towards 
methyl caffeate (31). CaeA was able to cleave methyl caffeate, yet was less efficient with 
a relative activity of 36 % as compared to 68 % activity towards ethyl ferulate. CaeA was 
furthermore shown to cleave the ester bond of 6-O-feruloyl glucose, thereby releasing 
glucose as detected by HPAEC–PAD (Figure 2.5).   
 
Esterase versus lipase substrate range of CaeA. The hydrolytic activity of CaeA 
towards several colorimetric substrates containing 4 to 12 carbons was also determined. 
‘True’ esterases generally recognize substrates that contain less than six carbons, whereas 
lipases may be active on substrates containing more than six carbons (39). The activity in 
these colorimetric assays was determined by the amount of released p-Np using a 
photospectrometer at 348nm. The mean specific activity of CaeA on p-Np butyrate is 8.35 
µmol min
-1
 mg-1. The activity of CaeA towards p-Np acetate, p-Np octanoate and p-Np 
dodecanoate was then determined relative to that observed for p-Np butyrate (which was 
set at 100 %) (Figure 2.6). From the obtained results it is clear that CaeA has a substrate 
preference for p-Np butyrate and appears to be functioning as a ‘true’ esterase since the 
enzyme elicits substantially reduced activity towards the longer chain substrates with just 
13.7 % and 15.7 % activity against p-Np octanoate (8 carbons in length) and p-Np-
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dodecanoate (12 carbons in length), respectively. CaeA also exhibits a lower relative 
activity of 40.8 % towards p-Np acetate. In contrast, other esterases from several 
lactobacilli species and B. animalis subsp. lactis DSM 10140 have been shown to exert 
maximal hydrolytic activity towards the shorter p-Np acetate, though exhibit low activity 
towards p-Np octanoate, a property they have in common with CaeA (66). Nonetheless, 
CaeA is not unique in exhibiting its preferred actitivy towards p-Np butyrate (31, 67).  
 
Optimum pH, Temperature and effect of ions on CaeA. The biochemical properties of 
CaeA were investigated to ascertain the reaction conditions for optimal activity of CaeA. 
The optimum temperature and pH were determined by measuring the release of p-Np, a 
colourimetric substrate at 348nm, from p-Np butyrate. Relative activity for each condition 
was calculated by normalising the data to the highest specific activity of CaeA, 12.65 
µmol min
-1
 mg-1 for pH and 25.40 µmol min
-1
 mg-1  for temperature, and expressing the 
data as a percentage relative to this value. The optimal temperature for CaeA was found 
to be 40°C and the optimum pH was 7.5 (Figure 2.6). The lowest activity of CaeA was 
observed at 55°C and pH 4.5, conditions that diminished activity to 25 % and 11%, 
respectively. Nontheless, CaeA appears to be a versatile enzyme, exhibiting activity 
across a rather wide range of temperatures and pH conditions. The effect of ions and 
detergents on CaeA was also investigated (Figure 2.7). No substantial impact on esterase 
activity was noted except for the addition of Cu2+ which reduced activity to 7%. Reduction 
of esterase activity by Cu
2+
 has been reported elsewhere in the literature (33, 68, 69).  
 
2.5. Discussion 
Members of the B. longum subsp. longum taxon have been specifically associated 
with complex plant carbohydrate metabolism, making these plant-derived glycans 
candidate prebiotics for these bifidobacteria. HCAs are frequently found esterified to plant 
carbohydrates that are indigestible to the human host and are therefore more likely 
released in the colon by particular members of the gut microbiota (40, 70-73). Much work 
on plant-derived poly/oligosaccharide metabolism in bifidobacteria has focussed on 
arabinofuranosidase and xylanase, β-glucosidase activities (9, 57, 74-76). However, since 
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HCAs are a component of plant carbohydrates it is also important to investigate if 
bifidobacterial produce esterases.  
In the current study we identified and biochemically characterised a novel HCA 
esterase from B. longum subsp. longum NCIMB 8809. Significantly, this esterase-
encoding gene was located within a highly conserved locus within the genome of all 
analyzed members of this taxon. The B. longum subsp. longum taxon is known to 
metabolise plant oligosaccharides such as arabinoxylan and arabinan (15), and therefore 
the genetic location of this esterase in an arabinoxylan/arabinan metabolism cluster 
suggests that HCAs that are attached to the arabinose residues of plant carbohydrates are 
cleaved off as part of the process of metabolising these complex plant cell wall 
carbohydrates (12, 21). This co-location of an esterase-encoding gene within a 
polysaccharide utilisation locus is similarly reported for other species of bacteria in the 
gut microbiota such as Bacteroides species (77, 78). Furthermore, these plant cell wall 
glycans have been reported to act as prebiotics stimulating bifidobacterial growth in the 
gut (79-81). In order to allow enzymatic access to these dietary polysaccharides 
bifidobacteria are likely to require an esterase to remove HCAs prior to the metabolism 
of the carbohydrate moiety. Nonetheless, Riviere and colleges found that the presence or 
absence of an esterase gene in bifidobacterial strains did not correlate to a strain’s ability 
to metabolise arabinoxylo-oligosaccharides (15). It must be noted that the actual specific 
constituents of arabinoxylan and AXOS are highly variable (21, 82), and that an esterase 
may therefore not be needed by all strains to metabolise certain AXOS constituents.  
We demonstrated that the purified CaeA esterase was active against a number of 
different substrates, such as feruloyl glucose and p-Np butyrate. Heterologous expression 
of CaeA in B. breve UCC2003 also conferred esterase activity to a bifidobacterial strain 
normally devoid of esterase activity. CaeA contains the general characteristic esterase G-
X-S-X-G motif, Ser-Asp-His catalytic triad and the conserved alpha/beta hydrolase 
structure typical of esterase and lipases. CaeA is a ‘true’ esterase rather than a lipase as it 
elicits a preference for smaller carbon backbone substrates less than six carbons. It has 
previously been reported that bifidobacterial esterases from B. animalis subsp. lactis WC 
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0432 and B. animalis subsp. lactis DSM 10140 exhibit hydrolytic activity against 
chlorogenic acid and artificial HCA-containing substrates (30, 66).  
Certain bifidobacterial taxa may be able to release HCAs from plant 
oligosaccharides in the gut and may make these phenolic compounds available for their 
own metabolic use, to the human host and/or to other members of the gut microbiota. 
HCAs have been reported to act as external electron acceptors and may thus provide an 
energetic advantage for heterofermentative lactobacilli by increasing the amount of ATP 
and NADH regeneration (36, 37). Increased bioavailability of the HCAs may also have 
consequences and/or reflect the disease state of the host. In diabetes-resistant rat models 
lactobacilli and bifidobacteria were found to be more abundant compared to diabetes-
sensitive rats (83); lactobacilli with an increased capability of HCA hydrolysis were 
isolated from the same patient sample set (26). However, it should be noted that 
conclusive proof for HCA metabolism by bifidobacteria is as yet lacking. 
Similar to the esterase from B. animalis subsp. lactis WC0432, CaeA is presumed 
to be an intracellular enzyme as based on the lack of an obvious protein secretion signal 
(30). Therefore, whether certain bifidobacteria increase bioavailablity of HCAs to the host 
still remains unclear. A limitation of our study is that we did not employ plant 
oligosaccharide substrates substituted by HCAs to test this as the plant oligosaccharide 
isolation process usually removes HCAs. Future work should determine if bifidobacteria 
can metabolise HCAs, and if so, assess the consequences of this ability for bifidobacterial 
physiology in the gut environment. Furthermore, the question should be addressed as to 
whether or not bifidobacteria release HCAs in their environment to make them available 
to the host or other gut microbes.   
In conclusion, this study has found that members of the B. longum subsp. longum 
taxon possess a highly conserved esterase-encoding gene, which is co-located with genes 
associated with plant poly/oligosaccharide degrading enzymes on the B. longum subsp. 
longum genome. Therefore, CaeA is likely an important enzyme in the metabolism of 
plant oligosaccharides by B. longum subsp. longum taxon. CaeA is a true esterase capable 
of cleaving several HCA and esterase model substrates and thus bifidobacteria a likely 
can release HCAs from plant oligosaccharides. B. longum subsp. longum is the second 
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known bifidobacterial species able to express an esterase that may remove HCAs from 
plant carbohydrates.   
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*Restriction enzyme sites are highlighted in bold.  
 
 
Table 2.3. HPLC anaylsis of CaeA activity against HCA substrates  
  HCA substrate Activity 
Methyl ferulate + 
Ethyl ferulate + 
Methyl p-coumaric acid + 
Methyl caffeate  + 
Methyl sinapinate** - 

























Figure 2.1. Comparison of the conserved plant oligosaccharide degradation locus amongst complete and available genomes of 
the B. longum subsp. longum taxon.  
B. longum subsp. longum strains are indicated in bold. The arrows represent open reading frames which are proportional to open reading 
frame length. The nucleotide identity of each of the open reading frames is calculated as a percentage of identity to the equivalent open 





Supplementary Figure S2.1. Esterase multiple sequence alignments. 
Multiple sequence alignment of CaeA (B8809_1755) from B. longum subsp. longum NCIMB 
8809, Balat_0669 from B. lactis subsp. animalis, Lp_1002 from Lactobacillus plantarum WCFS1, 
Lp_2923 from L. plantarum WCFS1 and lj0536 from Lactobacillus johnsonii N6.2. The (Gly – 
X – Ser – X – Gly) esterase motif is highlighted in the red box and the Ser-Asp – His triad residues 
are indicated by the red triangles.  
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Figure 2.2. Esterase Activity Plate Assay.   
Growth of B. breve UCC2003 (A), B. breve UCC2003 pNZ44 (B) and B. breve 
UCC2003 pNZ44_CaeA (C) on RCA supplemented with 0.1 % (w/v) ethyl ferulate 





















Figure 2.3. Purification of CaeA.  
The 12.5 % SDS-PAGE gel including protein standard ladder (lane 1), supernatant (lane 












Supplementary Figure S2.2. HPLC analysis of the activity of CaeA against 
hydroxycinnaminic acid substrates.  
Enzyme reactions were carried out in 20 mM morpholinepropanesulfonic acid (MOPS) pH 7.5 
with the substrates present at a 1 mM final concentration and 15 µg of CaeA protein per reaction 
in a final reaction volume of 1 ml. All substrates were also incubated in buffer without CaeA as a 
negative control. All reactions and negative controls were incubated at 37°C for 16 hours and were 
terminated by the addition of 370 µl ethyl acetate. Assays were performed in duplicate. CaeA 
activity against methyl ferulate and corresponding no enzyme control (A), ethyl ferulate and no 
enzyme control (B), methyl p-coumaric acid and no enzyme control (C), methyl sinapinate and 





Figure 2.4. Release of HCAs from methyl ester substrates. 
The relative activity of CaeA against synthetic HCA esters; methyl ferulate, ethyl ferulate 
and methyl caffeate (A). Assays were performed in 1mM NaH2PO4 K2HPO4 pH 7 at 37°C 
for 2 Hr with a protein concentration of 6µg/ml. Data is representative of mean values and 
standard error of the mean. * No measurable enzyme activity was found against methyl 
sinapinate. The structure of Methyl ferulate (B), Methyl sinapinate (C), Methyl Caffeate 
(D) and Methyl p-Coumarate (E). These structures were partially adapted from a previous 














Figure 2.5. HPAEC – PAD analysis of CaeA activity against feruloyl glucose.  
Glucose standard (1 mg/ml) (A). Feruloyl glucose (0.5mg /ml) standard (B). No enzyme 
control where feruloyl glucose is incubated for 16 Hrs at 37 °C (C). Undialysed CaeA 
incubated with feruloyl glucose after 16Hrs at 37°C (D). Dialysed CaeA incubated with 
feruloyl glucose after 16Hrs at 37°C (E). Assays were carried out in 0.1M sodium 
















Figure 2.6. Determination of substrate specificity, pH optimum and temperature optimum of CaeA.  
Maximal observed activity on p-Np buytrate was defined as 100 %. Optimum substrate preference assays were carried out in 0.1 M 
NaH2PO4 K2HPO4 buffer pH 7.5 at 37 °C (A). Optimum temperature assays were performed in 0.1 M NaH2PO4 K2HPO4 buffer pH 7.5 at various 
temperatures to ascertain the optimum temperature for CaeA (B). Optimum pH assays were performed at 37 °C in 0.2 M Citric phosphate buffer 
(Blue), 0.1 M NaH2PO4 K2HPO4 buffer (Red) and 50 mM Tris-HCL buffer (Purple) (C). All assays were carried out with p-Np butyrate as the 




Figure 2.7. Investigation of the effect of ions on the activity of CaeA. 
Investigation of the effect of ions on the activity of CaeA. Ions were added at a 1 mM final 
concentration and 100 % activity was defined as the activity of CaeA in the absence of any 
additive. Assays were performed at 37°C in 0.1 M NaH2PO4 K2HPO4 buffer pH 7.5 using p-Np 
butyrate as a substrate. Data is representative of mean values and standard deviation. Maximal 
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Chapter V  
 
Bifidobacterial biofilm formation is a multifactorial adaptive 
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In the current study, we show that biofilm formation by various strains and species 
belonging to Bifidobacterium, a genus that includes gut commensals with reported health-
promoting activities, is induced by high concentrations of bile (0.5 % (w/v) or higher) and 
individual bile salts (20 mM or higher), rather than by acid or osmotic stress. The 
transcriptomic response of a bifidobacterial prototype Bifidobacterium breve UCC2003 
to such high bile concentrations was investigated and a random transposon bank of B. 
breve UCC2003 was screened for mutants that affect biofilm formation in order to identify 
genes involved in this adaptive process. Eleven mutants affected in their ability to form a 
biofilm were identified, while biofilm formation capacity of an insertional mutation in 
luxS and an exopolysaccharide (EPS) negative B. breve UCC2003 was also studied. 
Reduced capacity to form biofilm also caused reduced viability when exposed to porcine 
bile. We propose that bifidobacterial biofilm formation is an adaptive response to high 
concentrations of bile in order to avoid bactericidal effects of high bile concentrations in 
the gastrointestinal environment. Biofilm formation appears to be a multi-factorial process 
involving EPS production, proteins and extracellular DNA release, representing a crucial 













5.2. Introduction.  
Biofilms are microbial communities that are attached to a surface and are 
enclosed/structured by an extracellular matrix (1). Biofilms may also form when free 
floating cells clump together or adhere to particulate matter, this being referred to as 
microcolony formation (2). Biofilm formation is a complex process involving multiple 
steps, including initial attachment, accumulation, maturation and dispersal (3). Initial 
attachment is reversible and can be driven by electrostatic interactions; attachment to a 
surface can also be mediated by cell wall-associated proteins that bind to a substrate-
covered surface or extracellular DNA (eDNA) release, where DNA released by cell lysis 
coats the surface and changes surface properties to allow attachment (4, 5). The 
accumulation phase of a biofilm can be mediated by cell wall associated protein 
interactions or extracellular matrix (EM) secretion (5, 6). The EM of biofilms may be 
composed of extracellular polysaccharide (EPS), DNA and/or proteins (7-9). Finally, 
following maturation, individual cells may disperse from the biofilm to resume planktonic 
growth (10). Biofilm formation is often triggered in response to environmental stresses, 
such as nutrient starvation, antibiotics, pH and bile, or induced through quorum sensing 
systems, such as the Agr or autoinducer-2 (AI-2) systems (11-14).  
Bifidobacteria are non-motile gut commensals, some of which are purported to 
exert health-promoting or probiotic properties (see review (15)). Particular bifidobacterial 
strains are for this reason included in certain ‘functional foods’ so as to bestow these 
benefits to the host that ingests them (16). However, whether bifidobacteria colonise from 
birth or are ingested as a probiotic they will encounter and must overcome stresses in the 
gastrointestinal tract (GIT), such as low pH, bile, osmotic stress and nutrient starvation, 
as well as compete with other members of the microbiota (17). Bile is present as a gradient 
along the GIT (40 mM to 0.5 mM), being highest in the small intestine and lowest in the 
colon (18, 19); however, bile/bile salt concentrations will vary greatly upon ingestion of 
(certain types of) food. 
Bile and its constituent bile salts represent a major stress-inducing factor to 
bacteria in the GIT environment due to their bactericidal properties (19-21). There are 
different types of bile salts since primary bile salts such as chenodeoxycholic acid or 
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cholic acid can be conjugated with either a taurine or glycine before secretion. Primary 
bile salts can also be dehydroxylated by the gut microbiota to form secondary bile acids 
which can also be conjugated by taurine or glycine (20). Bile salts are bactericidal and 
target and disrupt the bacterial cell membrane (20). In bifidobacteria bile resistance 
mechanisms include efflux of bile salts by multi-drug transporters (22-24), compositional 
changes of the cell membrane (25-27), F0F1-ATPase proton efflux (28), changes in 
metabolism (29-31) and hydrolysis of bile salts (32, 33). Bile has previously been shown 
to induce biofilm formation in certain gut commensals, such as particular species/strains 
of Bacteroides, bifidobacteria and lactobacilli (34-36). Therefore, it is important to study 
biofilm formation in commensal strains, such as bifidobacteria, and to obtain insights into 
how they adjust to and survive bile stress, and how this contributes to gut colonisation.  
Bifidobacteria have previously been shown to form microcolonies on the gut 
mucosal surface and food particulates isolated from the gut (37, 38). Currently, little is 
known about the molecular mechanisms of biofilm formation in bifidobacteria. Bile and 
bile salts at relatively high concentrations (0.5 % taurocholic acid and 5 % porcine bile) 
have previously been found to induce biofilm formation in bifidobacteria (34). In many 
bacterial species a specific quorum sensing signalling system is required for the induction 
of biofilm formation. For example, the AI-2 system involves LuxS, a S-
ribosylhomocysteinase, producing AI-2, which is released extracellularly, and then sensed 
by the LuxP, LsrB or RbsB receptors of two component systems which in turn cause 
transcriptional induction of genes involved in eDNA release and polysaccharide 
production, among others, biofilm formation (39-41). Previously, AI-2 activity has been 
detected by several bifidobacterial species and strains, while in addition the over-
expression of LuxS in Bifidobacterium longum subsp. longum NCC2705 has been linked 
to increased biofilm formation (42-44). The exposure and growth of Bifidobacterium 
breve UCC2003 to bile and bile salts has also been shown to cause increased transcription 
of luxS which is a homolog of the previously studied luxS in B. longum subsp. longum 
NCC2705 (24, 42). An insertion mutant in luxS in B. breve UCC2003 has previously been 
demonstrated to negatively affect gut colonisation ability in a mouse model (43). 
However, the effect of a luxS mutation on biofilm formation in B. breve UCC2003 was 
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not investigated. Besides these studies, essentially nothing is known about the molecular 
mechanisms of biofilm formation in bifidobacteria.  
The aim of this study was to identify at what physiologically relevant 
concentrations of bile/bile salts biofilm formation is induced, and to identify genes 
involved in bifidobacterial biofilm formation. Our findings indicate that biofilm formation 
is a multi-factorial response to high concentrations of bile which is likely to be crucial for 
survival and colonisation of bifidobacteria within the gut environment. 
 
5.3. Materials and Methods. 
 
Bacterial strains, culture conditions, media.  
All bacterial strains used in this study are listed in Table 4.1. Bifidobacterial strains were 
routinely cultured in reinforced clostridial medium pH 6.8 (RCM, Oxoid Ltd., 
Basingstoke, Hampshire, United Kingdom) or reinforced clostridial agar (RCA, Oxoid 
Ltd.). RNAseq experiments were carried out using cultures that had been grown in filtered 
RCM (fRCM). All bifidobacterial strains were grown anaerobically in a modular 
atmosphere controlled system (Davidson and Hardy, Belfast, Ireland). Where required, 
media was supplemented with tetracycline (Tet, 10 µg ml
-1
) or porcine bile, 0.5 % (w/v) 
or 1 % (w/v) (Sigma- Aldrich, Steinheim, Germany). Individual bile salts were purchased 
from Sigma-Aldrich. 
 
Crystal Violet Biofilm Assay. 
Overnight cultures of bifidobacteria (20 µl) were used to inoculate RCM supplemented 
with 0.5 % (w/v) or 1 % (w/v) porcine bile (Final volume 200 µl) in a 96 well microtiter 
plate. Biofilms were allowed to form for 24 Hrs at 37°C in anaerobic conditions and were 
then washed three times with deionised water to remove planktonic cells and left to dry 
for 1 hour. The biofilms were stained with 1 % crystal violet (100 µl) (Sigma-Aldrich) for 
1 minute and then washed three times with deionised water to remove excess crystal violet 
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stain. Crystal violet stained biofilms were then solubilised with 5 % (v/v) acetic acid (100 
µl) (Sigma-Aldrich) and the absorbance read at a wave length of 570 nm. 
 
Screening of a mutant library for biofilm defective mutants.  
A previously described transposon mutant library of B. breve UCC2003 (49, 50) was 
screened for mutants affected in their ability to from a biofilm. Individual transposon 
mutants were subcultured in RCM supplemented with tetracycline and RCM 
supplemented with 0.5 % and 1 % (w/v) porcine bile, to induce biofilm, for 24 Hrs. 
Biofilm formation was stained as described above. Transposon mutants that exhibited 
reduced biofilm formation were then selected for further analysis. The precise location of 
the transposon in a given mutant was then identified by iPCR as previously described (49, 
50) or by arbitrary primed PCR as previously described with modifications (65, 66). 
Round one of arbitrary PCR was carried out with primers Arb 1, Arb 6 and either TnTetR1 
or TnTetL1 (Table 5.2). The successful PCR reaction was then used in a second PCR 
reaction (round 2) using primers Arb2 and either TnTetR2 or TnTetL2 (Table 5.2). PCR 
reactions from iPCR reactions and round 2 arbitrary PCR reactions were then sequenced 
(Eurofins, Ebersburg, Germany) to identify transposon insertion with primers pMod-Fw-
seq and pMod-Rv-seq.  
 
DNA Manipulations.  
DNA manipulations were carried out as previously described (67). Oligonucleotides used 
in this study were synthesised by Eurofins (Ebersberg, Germany) and are listed in Table 
5.2. Genomic isolations from B. breve UCC2003 were performed as described previously 
(68). Inverse PCR and arbitrary PCR reactions to identify transposon insertion points, 
were carried out with the 2X Phusion Green HSII High Fidelity polymerase (Thermo-
Scientific) and Q5 High Fidelity DNA polymerase (New England Biolabs), respectively. 
All PCR products were purified using the High Pure PCR Purification Kit (Roche). 
Restriction enzymes (Sigma Aldrich) and T4 DNA ligase (Promega) were used as stated 




Transcriptomic analysis.  
An overnight culture of B. breve UCC2003 in RCM was used to inoculate (1 % v/v) fRCM 
and this culture was grown until an O.D.600nm between 0.5 – 0.6 was reached. The cells 
were then exposed to a bile shock by adding 0.5 % (w/v; final concentration) porcine bile. 
Following 20 minutes bile exposure cells were harvested by centrifugation, while a culture 
in fRCM to which no porcine bile was added was also harvested as a control. RNA 
extraction was carried out as previously reported but with modifications (69). In order to 
extract RNA, total RNA of each of the cultures was mixed with 800 µl of QIAzoL Lysis 
Reagent (Qiagen, UK) and pipetted in to a sterile tube with glass beads (Merck, Germany). 
Cells were lysed 2 minutes of stirring this mixture in a Precellys 24 homogenizer (Bertin 
instruments, France) with 2 minutes of static cooling; this step was repeated in triplicate. 
The lysed cells were centrifuged to remove cellular debris at 12,000 rpm for 15 min and 
the upper phase was collected. The RNA samples were purified using the RNAesy Mini 
Kit (Qiagen, UK) as per the manufacturer’s protocol. RNA concentration and purity were 
checked by a Picodrop microliter spectrophotometer (Picodrop, UK).  
 
RNAseq analysis performed by NextSeq Illumina. RNAseq analysis was carried out as 
previously described with modifications (70). A total of 2.5 µg of RNA was treated to 
remove ribosomal RNA by the Ribo-Zero Magnetic Kit (Illumina) for RNA sequencing, 
and the rRNA-depleted sample purified by ethanol precipitation. RNA was processed 
according to the manufacturer’s protocol. The yield of rRNA depletion was measured by 
a Tape station 2200 (Agilent Technologies, USA). The construction of the whole 
transcriptome library was carried out using the TruSeq Stranded RNA LT Kit (Illumina). 
Samples were loaded into a NextSeq High Output v2 Kit Chemicals 150 cycles (Illumina) 
as per the technical support guide. The reads were depleted of adapters, quality filtered 





Inhibition and Dispersal assays. In order to study the factors involved in the initial steps 
of biofilm formation, an inhibition assay was performed as previously described (54) with 
some modifications as follows. RCM supplemented with 0.5 % (w/v) porcine bile was 
inoculated with 10 % overnight B. breve UCC2003 wildtype (WT) strain and B. breve 
UCC2003::Bbr_430 (EPS
-
-negative phenotype) (51). The RCM was also supplemented 
with 0.95 mg/ml proteinase K (Sigma Aldrich),10 U/µl DNase1 (Sigma Aldrich) or 4 mM 
sodium (meta) periodate (Sigma Aldrich). Cells were left to form biofilm anaerobically 
for 24 Hrs at 37ºC, after which biofilm biomass was stained with crystal violet as 
described above. To investigate what mature biofilm biomass is composed of, biofilm was 
allowed to form for 24 Hrs as for the inhibition assay and treated as previously described 
with modifications (71). The planktonic phase was removed, and biofilms treated with 
0.95 mg/ml of proteinase K in 20 mM Tris-HCl or 5 U/µl of DnaseI in 5 mM MgCl2 for 
a further 24 Hrs at 37ºC anaerobically. Biofilms were then stained with crystal violet as 
stated above.  
 
Viability Assays. To access the viability of cultures after 24 Hrs growth in bile, overnight 
cultures of bifidobacteria were inoculated as above for biofilm assays into either RCM 
supplemented with 0.5 % (w/v) porcine bile or RCM only, as an untreated control, and 
incubated for 24 Hrs. After this culture medium was diluted in PBS and spot plated onto 
RCA. Plates were incubated for 48 Hrs anaerobically at 37ºC. Cultures were also grown 
in glass test tubes in the presence of 0.5 % (w/v) bile and allowed to form biofilm for 24 
Hrs. Biofilm was then washed three times with sterile water and a pipette tip was used to 
scrape biofilm from the surface of the test tube. Biofilm was then restreaked on RCA 









Biofilm induction in Bifidobacteria.  
 Bifidobacteria may encounter various stresses in the GIT such as acid and bile salt 
stress (17). In other bacterial species, acid stress (45), salt stress (46) and bile exposure 
are known to induce biofilm formation (47). Bile salt (and by inference bile itself) 
concentrations vary along the GIT between 1 mM and 40 mM (21). Therefore, we tested 
various conditions, using an established method for biofilm detection, the crystal violet 
assay, to investigate under what conditions biofilm formation occurs in bifidobacteria. 
Previously, biofilm formation by various bifidobacterial species had been detected by 
means of congo red and crystal violet staining assays, and shown to occur following 
exposure to 0.5 % taurocholic acid and porcine bile at 5 % (w/v) (34). As expected, and 
using the prototype bifidobacterial gut commensal B. breve UCC2003 it was shown that 
biofilm formation indeed occurs following (porcine) bile exposure. However, because bile 
concentrations fluctuate throughout the GIT, we wanted to assess if biofilm formation is 
induced by other conditions pertinent to the intestinal environment and to what extent this 
occurs by varying porcine bile concentrations (Figure 5.1). Our findings show that 
biofilm formation is not induced in B. breve UCC2003 by low pH or osmotic stress (NaCl 
or sucrose) as has been reported for other bacterial species (46). All tested bile 
concentrations were considered physiologically relevant, and the biofilm-inducing effect 
of porcine bile was clearly shown to be dose dependent. Under the conditions tested 
biofilm formation by B. breve UCC2003 did not occur to any appreciable extent at bile 
concentrations of 0.05 % and 0.1 % (w/v), whereas at higher bile concentrations, i.e. 0.5 
% and above, clearly detectable biofilms were formed by this strain (Figure 5.1A). Of 
note, addition of porcine bile to the RCM media did not cause a change in pH, and we 
therefore presume that the induction of biofilm formation is pH independent. Furthermore, 
we tested several bifidobacterial species/strains to assess if dose-dependent, bile-induced 
biofilm formation is exhibited by other members of the bifidobacterial genus. All 
examined bifidobacterial strains/species were indeed shown to produce a biofilm in the 
presence of 0.5 % or 1 % (w/v) porcine bile (Figure 5.1B). Therefore, biofilm formation 
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in the presence of high concentrations of bile seems to be a property elicited by multiple 
species/strains across the genus Bifidobacterium.  
Bile is a heterogeneous mix of various components including cholesterol, bile 
salts, proteins and bilirubin (20). We therefore wanted to assess if bile salts alone are 
capable of inducing biofilm formation. Both taurine and glycine primary bile salts were 
tested along with their dehydroxy derivatives to see if any particular type of bile salt acts 
as a specific inducer for this process. Using B. breve UCC2003 it was shown that biofilm 
formation was triggered by individual bile salts (Figure 5.2) and that biofilm formation 
typically occurs at higher concentrations of bile salts, i.e. 20 mM and 40 mM, while at 
lower concentrations, i.e. 1 mM and 10 mM, very little or no biofilm was observed. Both 
trihydroxy-conjugated bile salts, taurocholic acid (TC) and glycocholic acid (GC), and 
dihydroxy-conjugated bile salts such as taurodeoxycholic acid (TDC), chenodeoxycholic 
acid (CDC) or glycodeoxycholic acid (GDC) induced biofilm formation (Figure 5.2). 
Therefore, biofilm formation by bifidobacteria upon exposure to bile/bile salts is a 
common phenomenon and may represent an adaptation mechanism to specifically survive 
exposure to high levels of bile encountered in the GIT.     
 
Transcriptomic response of Bifidobacterium breve UCC2003 to a high 
concentration of bile.  
In order to determine the transcriptomic response of B. breve UCC2003 to a high 
concentration of bile and to assess whether these genes were implicated in biofilm 
formation (see below), this strain was cultivated to a corresponding O.D.600nm value 
between 0.5 and 0.6, and then exposed for twenty minutes to 0.5 % ((w/v) final 
concentration) porcine bile. Genes exhibiting transcriptional 
upregulation/downregulation following bile exposure, with an associated p-value of less 
than 0.05, are summarised in Table 5.3.  
Various genes predicted to be involved in transport and metabolism of 
carbohydrates were significantly upregulated following 0.5 % bile exposure. 
Transcription of a gene encoding a putative PEP-PTS system (Bbr_1594), which 
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previously was shown to be induced by glucose (48), was upregulated 6-fold under the 
imposed bile exposure conditions. Similarly, genes predicted to encode an ABC-type 
transporter permease (Bbr_1558), an ATP-binding protein for an ABC-type transporter 
(Bbr_1890), galactokinase (Bbr_0492), acetate kinase (Bbr_0771) and xylulose-5-
phosphate/Fructose-6-phosphate phosphoketolase (Bbr_0776) were shown to be 
transcriptionally upregulated under these conditions, indicating that carbohydrate uptake 
and active carbohydrate metabolism are associated with the adaptive response to bile 
stress. However, our results also show that transcription of other genes involved in 
transport and metabolism of carbohydrates was subject to downregulation upon exposure 
to bile. These included an ATP-binding protein of an ABC-type transporter system 
(Bbr_0808), a glucosamine 6-phosphate isomerase (Bbr_1248), a cellodextrin binding 
protein (Bbr_0106), 1-4 α glucan branching enzyme and others summarised in Table 5.3. 
Therefore, it seems that a specific response of increased carbohydrate metabolism is 
induced following the imposition of bile stress. 
A solute binding protein (SBP) of an ABC-type transporter (Bbr_0521) of the bac3 
family possibly involved with glutamate and histidine uptake was also downregulated. A 
presumed SBP (Bbr_0579) implicated involved in Zn/Mn transport and previously found 
to be upregulated under iron limitation conditions (49), was downregulated 31 fold. 
Transcription of genes predicted to be involved in polyketide synthesis (Bbr_0204/0205)/ 
fatty acid metabolism (Bbr_1719) also incur upregulation in response to bile shock. Other 
genes, whose transcription was shown to increase upon bile exposure, were predicted to 
be involved in cysteine metabolism (Bbr_0969), ATP production (Bbr_328/329), iron-
sulfur metabolism (Bbr_0911) and an ATP component of the oligopeptide nucleotide 
transporter OppD (Bbr_1202).  
Whether or not the genes involved in bile resistance and genes involved in biofilm 
formation are interconnected remains to be seen. Therefore, we decided to investigate 
which genes are involved in biofilm formation and to determine if these genes are akin to 





Screening of a transposon-mediated insertion mutant library of B. breve UCC2003. 
In order to identify genes involved in biofilm formation, a previously described 
transposon mutant library of B. breve UCC2003 (49, 50) was screened for mutants 
affected in biofilm formation. Biofilm induction was achieved employing exposure of 
individual mutants to high concentrations of porcine bile, 0.5 or 1 % (w/v), for 24 Hrs; 
biofilm biomass was stained using crystal violet, solubilised in acetic acid and an 
associated O.D.570nm measurement was taken to perform a semi-quantitative assessment 
of biofilm biomass. A reduced O.D.570nm value (compared to that obtained for the wild 
type strain B. breve UCC2003) indicated a reduction in biofilm biomass formation and 
suggested that the transposon had mutated a gene involved in biofilm formation. A 
positive control of B. breve UCC2003 and transposon mutants grown in RCM was also 
included to exclude mutants that were simply impaired in growth (OD600nm value being < 
0.5) which could have reduced biofilm biomass because of reduced cell numbers due to 
poor growth. The screen was carried out with RCM to prevent identifying mutants 
defective in growth of a single carbon source (as RCM contains both glucose and starch). 
Transposon mutants identified in the primary screen where retested in a confirmatory 
screen in triplicate to ensure no false positives were isolated. 10,000 transposon mutants 
were screened from the B. breve UCC2003-derived transposon library, resulting in the 
identification of eleven mutants that were shown to be clearly and consistently affected in 
their ability to form a biofilm (Table 5.4; Supplementary Figure S5.1).  
The location of the transposon in individual mutants was identified by direct 
inverse PCR (iPCR) amplification or arbitrary primed PCR and subsequent sequencing 
(see Materials and Methods) and predicted gene functions were assigned by BlastP 
analysis. Alongside these mutants two other previously described mutants in a gene 
encoding a predicted priming glycosyl hydrolase causing loss of EPS production (EPS-) 
and a mutant in the gene for the AI-2-producing LuxS enzyme were also tested (43, 51). 
All eleven identified transposon and the two additionally selected mutants tested exhibited 
reduced biofilm biomass compared to B. breve UCC2003 WT at 24 Hrs as determined by 
the crystal violet assay (Figure 5.3). The B. breve UCC2003 EPS- mutant was shown to 
elicit substantially reduced biofilm biomass as compared to the wildtype suggesting that 
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EPS is important in biofilm formation. Several genes involved in metabolism and 
physiology where found to be involved in biofilm formation, such as (i) nrdHIE, which 
encodes a ribonucleotide reductase, (ii) SerA2, a phosphoglycerate dehydrogenase/ 
thymidlate synthesis, (iii) Bbr_200, an NADH flavin reductase, (iv) Bbr_200, an AAA 
ATPase, and (v) glgP, a glycogen phosphorylase, which is an enzyme responsible for the 
breakdown of glycogen (52). Transposon-mediated disruption of genes that influence the 
composition and properties of the cell wall envelope also had an impact on biofilm 
formation, such as dapE. DapE is a N-succinyl-L,L-diaminopimelic acid desuccinylase 
part of the lysine/meso-diaminopimelate (mDAP) pathway that produces lysine for 
protein synthesis and both lysine and mDAP are required for peptidoglycan synthesis (53). 
A mutant in a gene responsible for type I fatty acid biosynthesis (fas) also exhibited 
reduced biofilm biomass. A total of three transposon mutants in accC were isolated from 
the transposon bank screen. The accC, accD and fas genes, putatively encoding the acetyl 
Co-A α chain, acetyl Co-A β chain and the fatty acid synthase enzymes, respectively, are 
adjacent to each other and mutations in these genes are believed to interfere with fatty 
acid biosynthesis. Furthermore, mutations in genes involved in amino acid metabolism, 
such as a predicted oligopeptide transporter OppD2 and a predicted peptidase PepX, were 
shown to affect biofilm formation.  
From the above mutant screen, it is apparent that biofilm formation is a complex 
process involving a diverse set of genes involved in, among others, EPS production, in S-
ribosylhomocysteinase production, as well as carbon, fatty acid and peptide metabolism. 
Some of the genes, such as Bbr_1719; involved in fatty acid synthesis (accC), and 
Bbr_1202 (oppD) found in the screen were also upregulated in response to high 
concentrations of bile. Therefore, we wondered if biofilm was a survival strategy in 
response to high concentrations of bile. 
 
Biofilm viability.  
Biofilm formation seems to be associated with bile resistance and in order to 
investigate if this biofilm forming ability is positively correlated with enhanced survival 
following bile exposure, B. breve UCC2003 WT, the luxS insertion mutant, the EPS- 
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mutant, as well as transposon mutants in accC and Bbr_201 were grown for 24 Hrs in 
RCM supplemented with (0.5 %; w/v) or without porcine bile. Culture media was then 
diluted in PBS and spot plated on RCA to determine viable counts. Under these conditions 
B. breve UCC2003 WT and accC mutant were shown to exhibit the highest survival level 
compared to any of the other mutants (Figure 5.4A). To test if the biofilm formed was 
viable after 24Hrs, these strains were also grown in test tubes in the presence of porcine 
bile (0.5 %; w/v) and left for 24 Hrs to allow biofilm to form. Biofilm was then scraped 
off with a pipette tip and restreaked on RCA supplemented with cysteine and 0.5 % lactose 
(Figure 5. 4B). The RCA plates were then incubated for 48 Hrs and any colonies present 
counted. Viable colonies could be recovered from biofilm of B. breve UCC2003 WT and 
for all the mutants even though these mutants had less biofilm biomass. Therefore, these 
results suggest that the biofilm biomass itself is viable and that biofilm formation can 
increase resistance to high concentrations of bile.  
 
Biofilm matrix composition.  
In other bacterial species, cell wall associated proteins, EPS and eDNA are 
involved in the initiation and accumulation stages of biofilm (46, 54, 55). Therefore, in 
order to get an insight into the initiation stages of biofilm formation, biofilms for B. breve 
UCC2003 wildtype were set up in microtiter plates as above but were also incubated with 
proteinase K, to degrade proteins, or DNaseI, to degrade eDNA, and sodium 
metaperiodate, to oxidise EPS/cell surface carbohydrates, in order to assess if proteins, 
eDNA or extracellular surface carbohydrates play a role in (the initial stages of) biofilm 
formation (Figure 5.5). Incubation with proteinase K, DNaseI and sodium (meta) 
periodate was shown to cause a reduced biofilm biomass after 24 Hrs as indicated as a 
reduced O.D.570nm value as compared to untreated B. breve UCC2003 WT (Figure 5.5A) 
biofilm suggesting that the attachment and accumulation phases are mediated by a 
combination of proteins, extracellular DNA release and carbohydrate secretion, 
presumably EPS mediated. This indicates that macromolecules such as cell wall-
associated proteins, eDNA and EPS are involved in the initial attachment and 
accumulation phases of bifidobacterial biofilm formation. The B. breve UCC2003 EPS-
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negative mutant appeared to produce substantially less biofilm biomass than the WT, and 
extended treatment with DNaseI and proteinase was shown to reduce biofilm yet did not 
abolish biofilm completely. Treatment with sodium (meta) periodate did substantially 
reduce biofilm formation suggesting perhaps other cell wall-associated polysaccharides 
are important in biofilm formation. In the latter context it is relevant to note that B. breve 
UCC2003 has been reported to contain two EPS clusters (51, 56). 
To investigate the composition of the EM of mature biofilms of the B. breve 
UCC2003 WT formed after 24 Hrs, biofilms were enzymatically treated with proteinase 
K and DNaseI to determine if protein and/or DNA contributed to the EM, respectively 
(Figure 5.6). Proteinase K was able to disperse mature biofilm of B. breve UCC2003 WT, 
whereas DNaseI could not. This suggests that while extracellular DNA release may be 
important in the initial stages of biofilm formation it may not be as important in 
established mature biofilm structures. Proteinase K could also not completely disperse 
biofilm in B. breve UCC2003 WT, suggesting that mature biofilm composition is a 
multifactorial process, involving multiple macromolecules. In fact, complete (mature) 
biofilm dispersal was only observed when the B. breve UCC2003 EPS- mutant was treated 
with proteinase K. This suggests that both EPS and proteins play an important role in 
mature biofilm formation.  
 
 
5.5. Discussion.  
 
Bifidobacteria are gut commensals and to survive in the GIT environment they must be 
able to survive bile exposure. Our findings show that bifidobacteria form a biofilm 
following exposure to high concentrations of porcine bile. Porcine bile possesses a 
glycine:taurine ratio which is similar to that of human bile (57). Previous studies 
characterising the bifidobacterial bile response used bovine bile, rather than porcine bile, 
while also employing bile/bile salts at lower concentrations than those shown to induce 
biofilm formation (24, 25, 28, 29). It is important to assess the bifidobacterial response to 
various concentrations of bile as there is a gradient of bile in the GIT. The transcriptomic 
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response of B. breve UCC2003 to a high concentration (i.e. 0.5 % w/v or higher) of 
porcine bile was also distinct from bile exposure to lower concentrations of bile, oxgall 
0.15 % (w/v) and cholate 0.06 % (w/v), as previously reported (24). The transcriptomic 
response of B. breve UCC2003 to a high concentration of bile was shown to involve 
specific response in carbohydrate metabolism. This is in agreement with previous 
proteomic studies assessing bile response, where the expression of glycolytic enzymes 
and pyruvate catabolism enzymes, such as acetate kinase and xylulose-5-
phosphate/fructose-6-phosphate phosphoketolase, was upregulated (29, 30, 58). Bile-
adapted bifidobacterial strains have a different carbohydrate preference as compared to 
WT strains (59). Therefore, bile shock seems to invoke specific changes in carbohydrate 
uptake, storage and metabolism that may be important to survive high bile concentrations.  
 Genes involved in bile resistance also seem to be connected to biofilm formation. 
Our findings show that on exposure to high concentrations of bile fatty acid biosynthesis 
is induced, which also contributed to biofilm formation. A mutant in accC was shown to 
elicit increased resistance to bile, which suggests that fatty acid synthesis is not only 
important for biofilm formation but also for bile resistance. Previous studies have reported 
that transcription of the fatty acid synthase genes is downregulated when bifidobacteria 
are exposed to bile (24, 27). However, these studies were conducted at lower 
concentrations of bile with either bovine bile and/or individual bile salts rather than 
porcine bile and this may explain this apparent discrepancy. It is unknown why fatty acid 
metabolism is important in bile resistance. It has previously been shown that bile induces 
biofilm formation due to its capacity to increase surface hydrophobicity of bifidobacterial 
cells (34). Therefore, changes in surface hydrophobicity and perhaps membrane 
permeability due to altered fatty acid synthesis may help to resist the bacteriocidal effects 
of bile. Similarly, OppD2 was shown to be upregulated and involved in biofilm formation. 
It has previously been reported that OppA production is upregulated in bifidobacteria 
upon exposure to bile and shown to allow increased uptake of oligopeptides (24, 60). 
Oligopeptide transporters have also been implicated in bile resistance in Lactobacillus 
salivarius (61), although the precise manner by which peptides are involved in biofilm 
formation and bile resistance is currently not clear.  
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Bifidobacteria have been shown to form biofilm in the GIT environment (37, 38). 
We identified various genes involved in biofilm formation and we have shown that some 
of the corresponding mutants exhibit reduced viability following growth in bile. The luxS 
mutant was previously shown to impact on GIT colonisation in a mouse model (43). 
Similarly, insertion in luxS has an impact on biofilm formation and colonisation 
persistence in lactobacilli (62). However, the effect of a luxS insertion was not found to 
be exclusively due to absence of AI-2 production, but due to specific metabolic effects, 
such as changes in fatty acid metabolism and cysteine/sulfur-containing amino acid 
metabolism (36, 63). Genes involved in cysteine synthesis were upregulated in B. breve 
UCC2003 under shock with 0.5 % (w/v) porcine bile. LuxS is responsible for 
bifidobacterial synthesis of AI-2, yet bifidobacteria appear to lack an AI-2 quorum sensing 
system such as LuxP and/or LsrB, and we can therefore only speculate as to the 
mechanism by which AI-2 production is linked to bile resistance (43, 64). The B. breve 
UCC2003 EPS- mutant has also been shown to be less resistant to 0.3 % (w/v) porcine 
bile, while eliciting a reduced colonisation persistence in the GIT of mice (51).  
We also show that biofilm formation requires different macromolecular factors: 
the initial attachment phase of biofilm seems to be dependent on eDNA, EPS and protein 
interactions, though eDNA does not appear to be as important in the mature biofilm 
structure. A limitation of our study is that we could not distinguish if genes were important 
for initiation or maturation phases due to the screen being carried out in microtiter plates. 
More investigation is thus needed to dissect which genes are important for each of the 
phases of biofilm development and to discern if the importance of luxS in biofilm is due 
to AI-2 production or metabolic changes.  
From our study we propose the following model of biofilm in bifidobacteria in 
response to high concentrations of bile based on our works findings and biofilm in the 
literature (Figure 5.7). High concentrations of bile (0.5 % and above) lyse bifidobacterial 
cells and may release intracellular signals such as AI-2 or oligopeptides to induce quorum 
sensing. Extracellular DNA released from lysed cells may also coat the surface and 
resulting additional electrostatic interactions that allow bifidobacteria to adhere. Bile 
increases hydrophobicity of the cell surface and allows initial attachment of bifidobacteria 
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to the surface by increased hydrophobic interactions with the surface. Increased fatty acid 
biosynthesis may also alter cell surface membrane properties and LuxS may produce 
metabolic changes to also alter the cell membrane composition. Secretion of EPS and 
protein interactions may then allow firmer attachment and accumulation of cells. 
Maturation of the extracellular matrix of the biofilm involves further EPS secretion and 
protein interactions. When high concentrations of bile decrease, the biofilm may disperse 
and bifidobacterial cells are free to grow planktonically again. Future studies will be 
needed to test this model for accuracy, while additional studies are also needed to 
determine how important biofilm formation is for bifidobacterial gut colonisation and 
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Table 5.3.  Genes transcriptionally upregulated or downregulated in response to 





















































Table 5.4.Transposon insertions isolated in crystal violet biofilm screen 
 
*Gene was isolated twice in mutant screen. (Distinct mutants in the same gene).   









Figure 5.1. Biofilm formation by Bifidobacterium breve UCC2003 under different stress conditions.  
Biofilm was allowed to form for 24 Hrs under various conditions including pH 4 – 6.8, sucrose 0.05 mM to 2 mM, NaCl 0.05 mM to 2 mM and 
porcine bile 0.05 % to 2 % (w/v) (A).. The pH of RCM was 6.8. Biofilm formation was assessed by crystal violet staining with absorbance read at 
O.D.570nm. Biofilm formation by several species/strains of bifidobacteria. Biofilm induced by addition of 0.5 % or 1 % (w/v) of porcine bile and 
allowed to form for 24 Hrs (B). Biofilm was stained with crystal violet and the absorbance read at O.D.570nm. Negative controls with just RCM (non-





Figure 5.2. Biofilm formation of Bifidobacterium breve UCC2003 in response to bile salts. 
Biofilm formation was induced by addition of glycocholic acid (GC), taurocholic acid (TC), chenodeoxycholic acid (CDC), taurodeoxycholic acid 
(TDC) and glycodeoxycholic acid (GDC) at concentrations of 1 mM, 10 mM, 20 mM and 40 mM. Biofilm was allowed to form for 24 Hrs, was 
stained using crystal violet and the absorbance read at O.D.570nm. Experiments were carried out in triplicate and error bars represent standard error of 

















Figure 5.3. Biofilm formation by mutants screened from a Bifidobacterium breve UCC2003 transposon mutant bank. 
A transposon mutant bank was screened using the crystal violet assay. Biofilm was induced with 0.5 % (w/v) porcine bile and allowed 
to form for 24 Hrs. An insertional mutant B. breve UCC2003 luxS, and EPS deficient strain, B. breve UCC2003 EPS
-
, were also screened. 
A mutant in biofilm formation was assumed to have reduced biofilm biomass, as compared to the wildtype, due to reduced absorbance 






Figure 5.4. Viability of Bifidobacteria after 24 Hrs growth in porcine bile.  
B. breve UCC2003 WT, B. breve UCC2003 luxS, B. breve UCC2003 EPS-, B. breve UCC2003 accC and B .breve UCC2003 Bbr_201 were grown 
in a microtiter plate in RCM supplemented with 0.5 % (w/v) of porcine bile (biofilm formation conditions) and incubated for 24 Hrs. Culture 
media was then diluted and spot plated on RCA to see if viable bacteria could be recovered and the CFU/ml was calculated (A). Experiments were 
carried out in triplicate and error bars represent standard deviation. Biofilm was also induced in testubes by growing the above strains in RCM 
supplemented with 0.5 % (w/v) of porcine bile and incubated for 24 Hrs (B). Supernant was removed and test tubes were washed twice to remove 
planktonic cells. Biofilm was then scraped off the test tubes, where formed, with a pipette tip and streaked out on RCA supplemeted with lactose 




Figure 5.5. Inhibition of biofilm attachment of Bifidobacterium breve UCC2003 WT and Bifidobacterium breve UCC2003 EPS- 
Inhibition of biofilm attachment of Bifidobacterium breve UCC2003 wildtype (WT)(A) and Bifidobacterium breve UCC2003 
exopolysaccharide deficient (EPS-)(B). Biofilm was induced by supplementing media with 0.5 % (w/v) porcine bile and was additionally 
incubated with DNaseI (10 U/ml), proteinase (0.95 mg/ml) or sodium (meta)periodate (4 mM) or left untreated. Biofilms were then left 
to form for 24 Hrs, biofilm biomass was stained with crystal violet and absorbance read at O.D.570nm. Maximal biofilm production was 
taken to be 100 % for B. breve UCC2003 WT and B. breve UCC2003 EPS- when comparing effects of DNaseI, proteinase and sodium 






Figure 5.6 Dispersal of mature biofilms of Bifidobacterium breve UCC2003 wildtype and B. breve UCC2003 EPS-. 
Dispersal of mature biofilms of Bifidobacterium breve UCC2003 wildtype (WT) and a B. breve UCC2003 derivative deficient in 
exopolysaccharide production (EPS-). Biofilm was induced by supplementation of media with 0.5 % (w/v) porcine bile and biofilms 
were allowed to form for 24 Hrs. Mature biofilms were then treated with DNaseI (10 U/ml) in 5 mM MgCl2 and 0.95 mg/ml proteinase 
K in 20 mM in Tris-HCl. Biofilms were stained with crystal violet and absorbance read at O.D.570nm. Biofilm formation of B. breve 







Figure 5.7. Model of biofilm formation by bifidobacteria induced by high concentrations of bile.  
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6.1 General discussion and future perspectives 
 
Bifidobacteria are gut commensals that colonise infants at birth and continue to be 
part of the gut microbiota throughout the human lifespan, albeit in diminished abundance 
as the human host ages. Therefore, particular members of the Bifidobacterium genus, as 
representative autochthonous gut bacteria, have successfully adapted to the metabolic and 
physiological challenges of the GIT environment and are able to successfully colonise this 
habitat. Some of the environmental challenges that bifidobacteria face include low pH, 
bile acids/salts, nutrient acquisition, anti-microbial peptides and competition with other 
members of the gut microbiota. Indeed, some probiotic bacteria, which are considered 
allochthonous with respect to the human gut and which are supplied in certain commercial 
products, are believed to be incapable of GIT colonisation (1). This inability to colonize 
a human host may also be reflected in the genomes of certain bifidobacterial species; for 
instance, Bifidobacterium animalis subsp. lactis has undergone gene loss and genome 
decay and this may have happened as a result of long-term, continued cultivation growth 
under commercial production conditions (2). Therefore, investigations to discover and 
understand mechanisms by which bifidobacteria colonize and survive in the intestinal 
environment are warranted, and based on this premise particular aspects of carbohydrate 
metabolism and bile-induced biofilm formation were explored in this thesis.  
Nutrient acquisition is vital for bifidobacterial survival in and colonisation of the 
gut. In the infant gut, breast milk provides HMOs which certain species/strains of 
bifidobacteria are adapted to consume either directly or indirectly through cross-feeding, 
and this is believed to be one of the main reasons why certain bifidobacterial species are 
highly prevalent and abundant in the infant gut. However, HMO levels reduce and 
eventually disappear as infants wean from breast milk and with the introduction of solid 
foods in the diet, and as a result the relative abundance of bifidobacteria in the gut 
substantially decreases. The relative abundance of members of the genus Bifidobacterium 
in the adult gut is reported to be between 4% and 6%, although this may vary among 
different populations. In order to survive bifidobacteria must be able to metabolise certain 
dietary carbohydrates to remain in the adult gut. In the adult diet such carbohydrates can 
be present in the form of fibre or plant-associated glycans derived from cereals amongst 
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other sources (3). Previous studies have shown that certain bifidobacteria are able to 
metabolize such plant-derived glycans, in particular the B. longum subsp. longum taxon 
(4, 5). However, plant-derived glycans are typically complex and sometimes insoluble 
polysaccharides, and metabolism of such carbohydrates is species/strain specific and may 
involve a range of enzymes encoded by multiple genetic loci. The scientific investigations 
described in this thesis were focused on plant-derived, arabinose-containing 
poly/oligosaccharide degradation by the B. longum subsp. longum taxon and included the 
functional characterisation of an esterase (Chapter II of this thesis) encoded by a gene 
located in a genomic locus presumed to be dedicated to arabino-oligosaccharide (AOS) 
metabolism (6). Furthermore, in Chapter III of this thesis three enzymes, presumed to 
represent an extracellular α-L-arabinofuranosidase, an extracellular arabinanase and an 
intracellular α-L-arabinofuranosidase, were assessed for their role in AOS metabolism. 
The obtained findings may explain certain carbohydrate utilisation differences with 
regards to arabinan and AOS metabolism between strains of the B. longum subsp. longum 
taxon. These findings also illustrate the complexity and apparent overlap between 
particular plant-oligo/polysaccharide metabolic pathways encoded by this taxon. 
Arabinan and AOS are therefore potential prebiotics for the B. longum subsp. longum 
taxon, although strain-specific metabolic abilities must be considered when developing 
arabinan/AOS-based prebiotic and synbiotics. Arabinan/AOS utilisation by bifidobacteria 
is believed to involve dedicated hydrolytic enzymes and transporters, which can be 
encoded by multiple distinct genetic loci. Therefore, the scientific findings of this thesis 
increased our knowledge regarding plant-derived poly/oligosaccharide metabolism, and 
specifically that of arabinan/AOS, in the B. longum subsp. longum taxon. Further studies 
should include the generation of isogenic mutants, phenotypic studies using a variety of 
different AOS substrates, and phenotypic complementation in order to determine the 
specific function of the genes involved in arabinan/AOS metabolism.  
Furthermore, how dependent are bifidobacteria on other microbial species for 
cross-feeding these plant-oligosaccharides? It has previously been shown that 
bifidobacteria can cross-feed on arabinogalactan degraded by Bacteroides spp. (7, 8). 
More research is needed into the specific cross-feeding strategies that seem to exist 
between Bacteroides and bifidobacterial species. Bacteroides spp. are known for their 
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ability to degrade complex plant glycans (9), and they are called ‘messy eaters’ that 
extracellularly degrade glycans releasing oligosaccharides for other GIT members, 
including bifidobacteria, to scavenge (10). More detailed studies are needed to understand 
these complex ecological interactions, which may then allow rational strategies to be 
exploited for the development of novel plant-derived oligo/polysaccharide prebiotics. 
However, this also requires that plant-derived glycans are purified to a high quality, that 
the detailed structural (DP, covalent linkages and sidechain substitutions) information of 
these carbohydrates is known and that sufficient amounts of oligosaccharides are purified 
to allow growth and transcriptional analyses. Currently, plant oligosaccharides are not 
widely available in sufficient amounts and at a reasonable cost, while characterising 
oligosaccharides requires specialist techniques and expensive equipment such as mass-
spectrometry, HPLC, HPAEC-PAD and NMR. Furthermore, following the acquisition of 
this information, animal models would need to be employed to assess the 
prebiotic/bifidogenic potential of a given oligosaccharide. Animal models may then also 
be employed to explore this research with arabinan/AOS as the main component of the 
supplied diet.   
In the gut bifidobacteria are likely to have access to a variety of carbohydrates and 
it is important that they choose the most energy efficient carbon source to metabolise as 
bifidobacteria are competing with other microbial species in the gut. It is therefore crucial 
to understand the regulatory mechanism that enables bifidobacteria to preferentially 
choose their carbon source. Carbon catabolite repression (CCR) has been described for B. 
longum subsp. longum with an unusual preference for lactose over glucose (11). 
Interestingly, in B. breve a non-CCR system of global regulation has been reported with 
the ability to simultaneously regulate the uptake of several carbohydrate utilisation loci 
(12), although the precise details of this regulatory process have yet to be discovered. 
Therefore, there is still much to be understood about regulation of bifidobacterial 
carbohydrate metabolism at a global level. At a local level, LacI-type regulators are the 
predominant biological tool used for transcriptional regulation of a genetic locus involved 
in the utilization of a particular glycan. In Chapter IV we describe the LacI-type regulator 
AauR, which was shown to bind to a previously predicted operator binding sequence, 
although the effector of this presumed repressor could not be identified. Different plant-
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oligosaccharides derived from hemi-celluloses and pectin have highly complex structures, 
yet in cases contain identical monomeric/oligomeric components and glycosidic linkages. 
Additionally, bifidobacterial genomes often contain multiple loci in different locations 
across the genome dedicated to the metabolism of dietary carbohydrates. It is likely that 
if bifidobacteria are provided with a buffet of plant-derived oligosaccharides to metabolise 
in the gut they must choose the most energetically favourable carbon source as they are 
competing for resources with other members of the microbiota. A better understanding of 
bifidobacterial transcriptional regulation of plant-derived oligosaccharides is needed to 
gain insights into preferential utilisation of prebiotic plant-derived carbohydrates.  
In order to survive in the gut bifidobacteria, whether they are part of a probiotic 
product or when trying to colonize the infant gut, must be able to cope with exposure to 
bactericidal bile salts and bile acids (13). Bifidobacteria have developed various strategies 
to circumvent the antimicrobial activity of bile/bile salts including compositional changes 
to the cell wall (14), removal by multi-drug transporters (15), and changes in carbohydrate 
metabolism (16). Bile has been shown to induce biofilm formation in bifidobacteria (17) 
and biofilm formation is induced when LuxS is overexpressed (18). In Chapter V, we 
show that biofilm is induced by high concentrations of bile and also uncovered some of 
the molecular players involved in biofilm formation (19), thereby significantly advancing 
the current knowledge on bifidobacterial biofilm formation. Additionally, biofilm was 
shown to elicit a protective effect against the bactericidal properties of bile. This 
knowledge aids in the understanding of how bifidobacteria survive in the gut environment 
and biofilm is clearly an important lifestyle choice for colonisers of the GIT as 
bifidobacteria appear to form microbial biofilms on food debris in the gut (20). 
Furthermore, the EPS
-
 mutant that had reduced biofilm formation, as described in Chapter 
V, was previously shown to have a reduced colonisation persistence and increased 
sensitivity to 0.3% (w/v) porcine bile (21). This indicates that biofilm formation and the 
resulting potential protection from bile contributes to bifidobacterial gut colonisation. 
Further studies may focus on employing a murine model to determine if other mutants 
with reduced biofilm capacity are compromised in colonisation ability. Biofilm formation 
may be important to consider when selecting and delivering bifidobacterial strains as 
probiotic supplements; bifidobacterial strains with a greater capacity to form biofilm may 
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have an enhanced ability of reaching the large intestine alive. However, further knowledge 
about the molecular mechanisms that enable bifidobacterial gut colonisation is needed. In 
addition, it will be very interesting to assess if and how biofilm formation protects 
bifidobacteria against other stresses such as acid pH or anti-biotics, which may in turn 
enhance our knowledge on the mechanism by which bifidobacteria survive in the 
physiologically challenging gut environment.  
The research described in this thesis has contributed to increased knowledge on 
bifidobacterial metabolism of arabinan/AOS, especially for members of the B. longum 
subsp. longum taxon and showed how complex and strain specific arabinan/AOS 
metabolism is within the B. longum subsp. longum taxon. This thesis showed that 
arabinan/AOS has a potential to be a prebiotic to stimulate the growth of strains in the B. 
longum subsp. longum taxon but also highlighted the need to understand the strain specific 
metabolism of bifidobacteria; therefore, it is important to choose the relevant strain and 
glycan/oligosaccharide in potentially products aimed at increasing bifidobacteria in the 
gut and enhancing their purported health benefits. This thesis also established that biofilm 
formation is an important and protective survival strategy for bifidobacteria in response 
to bile and is likely a key strategy for survival in the gut. Again, biofilm formation is 
another consideration in probiotic/synbiotic products that potentially aid probiotics 
survival in reaching the large intestine alive. Overall, this thesis increased our 
understanding of how bifidobacteria survive and persist in the gut environment which has 
implications when considering strains and prebiotics designed to increase bifidobacterial 
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